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1. INTRODUCTION 
In the 21st century, we are living in the massive development of science and 
technology world. Yes, scientific technics made our life very easy and luxurious. The 
communication and technology made the world within our hand with the help of 
computer.  
Eventhough we are comfortable with a modern life, for that each and every 
day we have to run as much as possible to know the up-to-date changes in the 
technology, But the science and technology doesn’t provide a peaceful life. 
People may get tired, because of their fast and mechanical life. Now they want 
peaceful mind and natural life. For that purpose all of them turn to look on our 
traditional system of medicine – SIDDHA. 
 
THE UNIQUE SPECIALITY OF SIDDHA SYSTEM : 
 The Siddhars are supreme human beings, the immortal masters of meditation 
and also founders of the Indian traditional alchemical system of medicine namely 
“The Siddha System”. This system was bloomed by vast knowledge. Siddhars 
realized the truth by understanding the life force and maintaining the relationship 
between the causal body (Bio Magnetism) and the universal magnetism by their 
power of intelligence, They had formulated the method and maintain the quality of 
these two. Siddhars have left their imprints not only in medicine but also in Yoga, 
Alchemy and Philosophy. 
 
MAJOR ROLE OF PAEDIATRIC DEPARTMENT: 
 The healthy children are the backbone of a healthy society. So the department 
of Kuzhanthai Maruthuvam is trying to establish the good health of every child. 
 The treatment of children is not a easy way, It is a difficult one. Because they 
cannot tell us, what they felt. Especially before they start to speak, here only the 
physicians diagnostic skill to help us. 
  In siddha, the paediatrics is called as, Kuzhanthai Maruthuvam, Balavagadam 
and Pillaipini Maruthuvam.  
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ABOUT THE TOPIC: LASUNATHABITHAM 
 According to WHO, recent publication indicates Respiratory and Nutritional 
diseases are major life-threatening diseases in children especially in developing 
countries like India. 
The author have seen a lot of children in out patient ward of paediatric 
department those who are suffered by Tonsillitis. The symptoms are pain in throat, 
hoarseness of voice, odynophagia, dysphagia and halitosis. Their parents also worried 
about their immunity and complaint whether he/she not able to concentrate on their 
studies, etc... 
 So the author decided to choose LASUNATHABITHAM is also called as 
TONSILLITIS in modern term, for this dissertation because of this disease is more 
common in our country. Which is more common in all type of age group but it 
produce a complication in paediatric age group. So the author has taken this disease 
and undergone a dissertation work with a help of siddha drug “SUGANTHA MALLI 
CHOORANAM”. 
 
CONCLUSION: 
 I would like to say that if siddha treatments are available conveniently, they 
can benefit their overall health in many ways, people suffering from chronic ailment 
can get quick respite from these medicine and other can uses them as preventive 
agents that keep you healthy. Let us try to spread the knowledge of siddha medicine 
and do well for the public.   
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2. AIM AND OBJECTIVES 
AIM  : 
The principle aim of the study is to evaluate the clinical efficacy of the trial 
drug, “Sugantha Malli Chooranam” in the treatment of disease “Lasunathabitham” 
without any side effects and also to ensure a new approach in the diagnosis and 
treatment of disease. 
 
PRIMARY OBJECTIVE: 
To evaluate the clinical efficacy of the drug “Sugantha Malli Chooranam” to 
reduce tonsillitis and its presentations . 
 
SECONDARY OBJECTIVE: 
To correlate the signs and symptoms of “Lasunathabitham” with modern 
aspect. To study the Biochemical, Pharmacological and Antimicrobial activity of the 
drug towards the efficacy of the medicine. Along with the analysis of Siddha 
investigation techniques such as Envagai Thervu,  Neerkuri, Neikuri are to be done. 
  
4 
 
3. REVIEW OF LITERATURE 
SIDDHA  ASPECT 
-zSe!kihqkl<<<<!
Kd;Diu:;;;  
  Foe;ij gpuhaj;jpy; cz;lhFk; Neha;fspy;, mf;Foe;ijapd; tho;ehs; 
KOtJk; jhf;Fk; jd;ikAilajhd Neha;fspy; kpfTk; Kf;fpakhdJ “,yRd 
jhgpjk;” MFk;. 
 ,yRdkhdJ Foe;ijapd; njhz;ilapd; ,Ugf;fthl;bYk; gf;fj;jpw;F 
xd;wha;  mike;Js;s Xh; cWg;ghFk;. ,J  Foe;ijfspd; tha; kw;Wk; 
%f;Fj; Jthuq;fspd; topNa cl;GFk; te;ijfis Rthr kz;lyq;fSf;Fs; 
cs; Eioe;J tplhjgb ghJfhj;Jf; nfhz;bUf;Fk; kpf cd;djkhd 
Ntiyia nra;J tUfpwJ. vdNt> Foe;ijf;F Rthr njhw;WNeha; 
cz;lhfhky; fhg;gjpy; ,yRdk; kpf Kf;fpa gq;F tfpf;fpwJ. 
 mbf;fb cz;lhFk; ,yRd jhgpjj;jpdhy;> mf;Foe;ijapd; ,Ujak;> 
rpWePufk;> %is Mfpaitfs; jhgpjkile;J> mf;Foe;ijapd; tho;ehisNa 
Nfs;tpf;Fwp Mf;fptpLkhjyhy;> Foe;ijf;F cz;lhFk; ,yRd jhgpjj;ij 
cld; fz;lwpe;J> KOikahd jPh;T fhz;gJ mtrpakhfpwJ. 
 vdNt> ,t; Ma;Tf; fl;LiuahdJ> Foe;ijf;F cz;lhFk; “,yRd 
jhgpjk;” gw;wp tphpthf vLj;jpak;GfpwJ. 
OuX!ohbi<gt<!< << << < lx<Xl<!< << << < ohbi<< <<!giv{l<!;<<< !
   “-zSe! kihqkl<”! wEl<! osiz<! hz! uqtg<gTme<! hz<OuX! Fiz<gt<!
wMk<kqbl<HgqxK/! njugTt<?! TV! sil<hsqul<! hqt<jt! lVk<Ku! osiz<!
ngvikqbqz<?!gQp<g<gi[liX!“zSe!kihqkl<”!wEl<!osiz<!uqtg<gh<hMgqxK/!!
• n{<{k<kqzqVg<Gl<!sjkg<Ogx<hMl<!Oug<giM/!
• d{<{ig<Gk<kz<!
• dt<fig<G!fQ{<M!uti<f<K!oki{<jmjbg<!Gk<kq!fqx<xz</!
• d{<{ig<G!Ovigl<!
• d{<{ig<gqz<! sjk! uti<f<K! uQg<gk<jk! d{<mig<gq! -VljzBl<?!
nXGkjzB!L{<mig<Gl<!Ofib</!!
• n{<{ig<gpx<sq!
• Olz<uibqe<!gQp<h<Hxk<kqx<!gi[l<!kihqkl<!
• d{<{ig<gpx<sq!
!!.TV!sil<hsqul<!hqt<jt!lVk<Ku!osiz<!ngvikq/!
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!! -kjeOb?! “G{himl<! kiK! sQu! uGh<H< Q << Q << Q < ”! (lV/-vi/kqbigvi\e<?!
wz</J/wl<)!wEl<!Fizqz<?!
• n{<{ig<Gk<!K~X!kihqkl<!!
we<X!Gxqh<hqmh<hm<Mt<tK/!!!!
!! OlZl<?!-zr<jg!sqk<k!lVk<Ku!gzifqkq!lV/Os/squs{<Lgvi\i!wPkqb!
“Gpf;ij kUj;Jtk;; ; ;; ; ;; ; ;” vDk; Ehypy;> 
• oki{<jmbqz<!utVl<!sjk!!!!!!!!!!!
• oki{<jm!gqvf<kq!uQg<gl<!!!
• jsk<kqbg<gm<c!
!! weUl<!Gxqh<hqmh<hm<Mt<tK/!!!!!!!                                                     !
• oki{<jm!K~X!
• oki{<jmg<!gm<c!
• oki{<jm!OfiU!!! ! ! !!!!!!
Nkivl<!.!lexicon vol 5!klqp<!ngvikq!!
)hg<g!w{<!31:3?!31:4*!
-bz<;<<< !
GtqIf<k! ke<jlbie! d{U?! fQI! Lkzqbux<xiz<! Jbl<! nkqgiqk<K!
oki{<jm!gqvf<kqgtqz<!uQg<gk<jk!Wx<hMk<Kl<!Ofib<!-zSekihqkl<!NGl</!
! ! ! .!!Gpf<jk!lVk<Kul<!!
! ! ! !!lV/Os/squs{<Lgvi\i!M.D(S) (hg<g!w{<!368*!
-zSel<<<<!+ kihqkl<<<< 
 -zSel<!
-zSel<!we<hK!oki{<jmbqe<!ng<gl<!hg<gr<gtqz<!ole<!n{<{k<kqe<!
Le<! hqe<! fqjzgTg<G! -jmbqz<! hg<gk<Kg<ogie<xib<! -Vg<gqx!
Ouh<hr<ogim<jm!uculie!-v{<M!dXh<HgtiGl</!
 kihqkl<!
kihqkl<! we<hK! dml<hqe<! wh<hGkqbqziuK! $M! d{<migq! squf<K!
uzqBme<!d{<miGl<!uQg<gl</!OlZl<!nu<UXh<Hgtqz<!npx<sq!Wx<hMl</!weOu?!
zSe! kihqkk<kqz<! zSel<! kihqkljmf<K! squf<k! fqxljmkz<?! Svl?<!
oki{<jmbqz<!uzqBme<!%cb!uQg<gl<!Ngqb!GxqG{r<gt<!Wx<hMl</!
. dmx<%X!lV/-vi/kqbigvi\e<!wz</J/wl<!
Ofib<!<<< uVl<!upq;!!<<< !
giv{l<<<<;!
)n*!!“oki{<jmkeqz<!Ofib[Gl<!giv{f<kie<!
!!!!!! $m<slkib<!osiz<ZgqOxe<!Sglib<!OgT!!
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!!!!n{<mi<!Lkz<!Okui<gjt!nhlieqk<Kl<!!
ncbijv!lqg!hpqk<K!kim<s{qk<Kl<!
!!!ogi{<mujv!Oh{ilz<!kib<!kf<jkg<Gl<!!
ogiMjl!lqg!osb<K!Ogihqk<Ok!kie<!
!!!h{<cbK!fqjxb!d{<M!hsqk<Okii<g<gQbi!!
hikgx<Gl<!oki{<jm!OfibEGK!ole<Ox”/!
. lkjzOfib<!okiGkq.II!
Dr.T.Nkhfduh[; gf;f vz:;300 
ohiVt<;<<< !
oki{<jmbqz<!wPl<!Ofibqe<!giv{k<jk!uqtg<gg<!Ogtib<?!leqki<gt<!
Lkz<! Okui<gjt! nhlieqk<kkiZl<?! -jx! hg<ki<gjt! hpqk<Kl<?! nx<hlig!
OhsqbkiZl<?! ke<je! n{<cbui<gjt! dkisQel<! hMk<kqbkiZl<?! kib<!
kf<jkbi<gjt! Ogihqk<K! ogiMjlh<! hMk<kqbkiZl<?! kie<! fe<xig! Hsqk<K?!
hsqk<K!gqmh<OhiVg<G!kvikkiZl<!oki{<jm!Ofib<!Wx<hMgqxK/!
!
)N*!-zSe!kihqklieK!ghg<Gx<xk<kqeiz<!Wx<hMukiz<!gh!Ofib<gTg<Giqb!
Ofib<!uVl<!upqOb!-kx<Gl<!ohiVf<Kl</!
! “lQxqOb!kqk ;jpg; GGspg;Gj; jhDk; 
   kpfj;jpd;Dq; fpoq;Ftif aUe;jp dhYk; 
 rhwpNa rgpjpjpakhq; Fsph;e;j gz;le; 
    jz;zPh;jhd; gioaJfs Uj;j yhYk; 
 ............................................................................................. 
    .......................................................................................... 
 .......................................................................................... 
    tUFNk Nrl;gj;jpd; kfpik jhNd. 
     -!B,gq!Leq!juk<kqb!sqf<kil{q!911!
! ! ! ! ! !lV/g/ne<hvS!BSMS 
       hg<gl<!w{<;264!
ohiVt<;<<< !
• lqGf<k!Gtqi<!gix<xqzQMhmz</!
• lqG! Gtqi<s<sq?! lqGf<k! ouh<hl<! dt<t! ohiVm<gjt! lqGkqbig!
d{<{z</!
• -eqh<H?!Htqh<H!SjuBt<t!ohiVm<gjt!nkqgl<!d{<[ukiZl</!
• Gtqi<f<k!fQi<<?!hjpb!OsiX!Ngqbux<jx!dm<ogit<ukiZl</!
• gqpr<G!ujggjt!nkqgl<!d{<hkiZl</!
• KiS?!Hjggtqz<!=MhMukiZl<!-f<Ofib<!d{<migqxK/!
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!
 (,) “rPh;ngU khh;Gjd;dp;w; nrwpe;jpLQ; Nrw;gde;jhd; 
    rhh;ngW kpdpg;gpdhYe; jhq;fpa RikapdhYk; 
    ePh;kpff; nfhs;ifahYk; epuk;GK]< zj;jpdhY 
    Nkh;ngW tpah;itahY nkOk;gpL nkd;W nrhy;Ny”. 
      - jd;te;jphp itj;jpak; (Kjy; ghfk;) 
        Dr.S.ntq;fluh[d; L.I.M 
   hg<gl<!w{<.77 
“jd;te;jphp itj;jpaj;jpaj;jpd;; ; ; ; ; ;; ; ; ; ; ;; ; ; ; ; ;” gb> 
• khh;Gjd;dpy; NrUk; rpNyw;gdj;jhYk; 
• mjpf ,dpg;G cz;gjhYk; 
• Rik Rkg;gjpdhYk; 
• Fsph;e;j ePh; kw;Wk; c];zj;jpdhYk; 
• mjpf tpah;it Mfpa fhuzq;fshy; fgNeha;fs; cz;lhfpwJ. 
,yRd jhgpjj;jpd; G; ;; ;; ; +h;t&gk;:; ;; ;; ;  
        “mf;fpdp ke;je; njhz;il ahpFu ydk;nt Wj;jy; 
    ff;fpa tpUky; njhz;il fhe;Jjy; jpdTz;lhjy; 
    njhf;fpdpw; RuKz;lhjy; #Ls gjhh;j;je;Njl 
    ..........................................................................nkd;dyhNk”. 
      - jd;te;jphp itj;jpak; (Kjy; ghfk;) 
       Dr.S.ntq;fluh[d; L.I.M 
         hg<gl<!w{<.211 
ohiVt<;<<< !
• grpapd;ik 
• njhz;ilf;fk;ky; 
• Mfhuj;jpy; ntWg;G 
• ,Uky; 
• njhz;il fhe;Jjy;> jpdTz;lhjy; 
• Ruk; 
• #lhd gjhh;j;jq;fspy; ,r;ir  
Kjyhditfs; ,e;Nehapd; G+h;t&gq;fshFk; 
!
Ofibqe<!Lx<GxqG{r<gt<< < < << < < << < < <; 
• oki{<jm!dzi<kz<!
• -Vlq!-Vlq!oki{<jmjb!squg<g!osb<kz<?!nkeqe<Xl<!Ogijpjbk<!
Kh<hz</!
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• oki{<jmbqz<!WOki!H,sqbK!OhiZl<?!oki{<jm!-Xg<gqbK!Ohie<Xl<!
d{i<s<sqB{<mikz</!
• Kl ;ky;> %f;F ePh; gha;jy;> %f;filg;G> Fuy; xyp Ntw;Wik 
miljy;.!
. sqk<k!lVk<Ku!Ofib<fimz<!Ofib<Lkz<!fimz<!kqvm<M 
!)-v{<mil<!higl<*!Dr.k.rz;KfNtY!HPIM!hg<gl<!w{<.8:!
ujggt<<<<;!
-zSe! kihqkk<kqe<! ujggt<! hz<OuX! Fix<gtqz<! hz! uqklig!
Gxqg<gh<hm<Mt<te/!!
njugTt<;!
 “5559! uqbikqgt<<<<”! wEl<! Fizqz<! mig<mi</s/nvr<gvise<! Nsqiqbiqe<!
%x<Xh<hc!.!gPk<Kg<G!gQp<!dt<t!Ofib<gjt!uquiqg<Glqmk<kqz<?!
 ‘dkqvs<!sbLl<!dbi<f<k!fQi<g<!gMh<Hl<!!
!g{<mf<!ke<eqz<!guqf<k!nmg<gLl<’//////!weg<!%xqBt<tii</!
!! ! ! ! ! !!!!!!!!!!!!!!!!!hg<g!w{<!.!32!
!! -ke<<!<<< ohiVt<!%Xlqmk<K! ‘oki{<jm!njmh<H’!we!uqtg<gqBt<tii</!-K!
-zSe!kihqkk<jk!Gxqh<hkiGl</!!!
ohiVt<<<<;!
!!! dmzqz<! Jbl<! lqGf<K?! fQi<g<gMh<Hl<?! oki{<jmbqz<! ghl<! njmk<Kg<!
ogit<Tl</!
 “guuhrNrfuk;;;;-rpuNuhfepjhdk;;;;” vDk; Ehypy; jiy> fOj;J Neha;fs; 
1008 vd tifg;gLj;jg;gl;Ls;sJ. ,jpy; dt<fig<G!Neha;fs;.31!vd 
$wg;gl;Ls;sJ.!
“MFnkz; zhd;F je;j kdpjNeha; ehw;ge;ije;jhk; 
 NjhifNa rpFit jd;dpy; NuhfKQ; nrhy;Yq; fhiy 
 ehfkh KdpA iuj;jhd; Kg;gj;jp ehyh nkd;dg; 
 ghfkh awpAz; zhf;fpw; gw;WNeh apUg jhNk; ; ; ;; ; ; ;; ; ; ; ” 
- guuhrNrfuk;-rpuNuhfepjhdk; 
 
 ,jidNa “sqk<ki<!nXju!lVk<Ku< < << < << < < l<< <<” <!<<< wEl<!FiZl<!%XgqxK/!
!.!sqk<ki<!nXju!lVk<Kul<!
  Dr.C.S/dk<klvibe<!
!hg<gl<!w{<!.!236!
 “svOhf<kqv! juk<kqb< << << < ! Ljxgt<<<<! )sqOviOvig! sqgqs<js*<<< ”! wEl<! Fizqe<!
%x<Xh<hc?!oki{<jmOfib<gt<.!26!ujg!d{<M/!
njubiue;!
! ! 2/!uik!Oki]g<OgitiiqeiZ{<miGl<!oki{<jmOfib<!
9 
 
! ! 3/!hqk ;j Oki]g<OgitiiqeiZ{<miGl<!oki{<jmOfib<!
! ! 4/!ghk<kqeiz<!Wx<hMl<!oki{<jmOfib<!
! ! 5/!-vk<kg<!OgitiiqeiZ{<miGl<!oki{<jmOfib<!
! ! 6/!^f;epghj Nuhfpzpapy; Wx<hMl<!oki{<jmOfib<!
! ! 7/!giZigl<!
! ! 8/!u<Vf<kl<!
! ! 9/!K{<cOgiqgi!
! ! :/!g<Otigl<!
! ! 21/!uzbl<!
! ! 22/!gitBgl<!
! ! 23/!skg<eq!
! ! 24/!gt!uqk<vkq!
! ! 25/!gtii<Hkl<!
! ! 26/!gtg{<ml<!
!! -f<k!gtg{<mlieK!OlZl<!5!ujgbig!hqvqg<gh<hm<Mt<tK/!
njubiue;!
2/ uik!gtg{<ml<!
3/ gh gtg{<ml<!
4/ OlOki!)ogiPh<H*!Oki]l<!nkqgligqz<!Wx<hMl<!gtg{<ml<!
5/ ^<uvg<el<!)Gvjzg<!ogMh<hK*!
!.!svOhf<kqv!juk<kqb!Ljxgt<!)sqOviOvig!sqgqs<js*!
!!=.K.th]_Njt rh];jphp B.A 
     Dr.S.ntq;fluh[d; LIM 
 “\Quvm<silqi<klQ < <Q < <Q < < << <<” << <<!wEl<!djvbqe<!%x<Xh<hc!oki{<jmOfib<gt<.!29!
ujggt</!
.!Sh<hqvl{qb!h{<cki<!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!!!!!hg<gl<!w{<;364/!
 OlZl<!-zSe!kihqkk<kqe<!GxqG{r<gjt!fq{g<Gvz<!gl<lz<!we!
“sqk<k!lVk<Kuk<kqz<!)ohiK*< < < << < < << < < < ”!Gxqh<hqmh<hm<Mt<tK/!
!
fq{g<Gvz<!gl<lz<!;< < < << < < << < < < !
“Gvz<ujt!fq{r<Ogijp!ogi{<M!kmuz<!Ohiz<!< < < < << < < < << < < < < !
uqvUuPh<!jhg<G{<fQi<!Oum<g<jg!< < < Q < < << < < Q < < << < < Q < < < .!kVOlz<<<<!
!! ! u{h<Ohs<!sxquqe<jl!uib<ohiXk<Kh<!Ohsz<!< < < < < < << < < < < < << < < < < < < !
! ! ! !fq{g<Gvx<!gl<l!oexq< < << < << < < ”/ 
! !
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ohiVt<<<<;!
 -f<Ofibqz<! dmzqz<! ogiPh<H! lqGf<K! nK! oki{<jmjb! njmf<K!
outqbiGl<! Ohs<osizq! ng<ogiPh<hiz<! kMg;fg;gl;L Gvz<gl<lz<!
d{<miGl</  
 clypd; ogiPh<H!Gjxb!Gvz<gl<lZl<!GjxBl</ 
 fq{g<Gvz<gl<lz<! Ofibqz<?! sqXubkqei<g<G! Gtqi<gix<X?! Gtqi<f<k! fQi<?!
d{U! -ux<xiz<! oki{<jm! squf<K! Jbr<%c! oki{<jmbqz<! sjk!
utVl</!
 -s<sjk! fiTg<G! fit<! uti<f<K?! Gvz<ujtjb! -Xg<gq?!
Gvz<gl<lz<!Ofijb!d{<mig<Gl</!
 -k<Kme<! Svl<?! oki{<jmOfib<?! uib<fix<xl?<! &g<gqz<! fQi<! uckz<?!
gikqz<!sQp<!uckz<?!-Vlz<!Okie<Xkz<?!&s<Sk<!kjmhmz<!Lkzqb!
GxqG{r<gjtBl<!gim<Ml<!we<X!%xqBt<tei</!
.sqk<k!lVk<Kul<)ohiK*!
!!)hg<gl<w{<!311, 312*!
!
 “B,gq!Leq!juk<kqb!sqf<kil{q!911< << << < ”!wEl<!Fizqz<!%xh<hm<Mt<t!
uqv{!sqOzk<Klg<!GxqG{r<gt<!-zSe!kihqkk<kqe<!GxqG{r<gOtiM!
yk<Kt<tK/!
!
uqv{!sqOzk<K<<< ll<;< << !
“kioee<x!oki{<jmbqeq<x<!H{<[!ligqs<!
! ! stqObiM!sQb<k<kiEr<!gzf<K!uQPl<!
! gioee<x!gPk<!OkiM!hqmiq!ge<el<!
! ! gelig!uQr<gqOb!gis<s!Z{<mil<!
! Ogioee<x!GtqOviM!wiqU{<!miGl<!
! ! ogig<oge<X!-VlqOb!%uZ{<mil<!
! Ouoee<x!lqmoxz<zil<!fiUl<!H{<Ohiz<!
! ! lqguqv{!sqOzm<M!lk<kqe<!uqhvf<!kiOe” 
     -!B,gq!Leq!juk<kqb!sqf<kil{q!911!
! ! ! ! ! !!lV/g/ne<hvS!BSMS 
         hg<gl<!w{<;272!
ohiVt<<<<;!
• uqv{!sqOzk<Klk<kqz<!oki{<jmbqz<!H{<{igq!stqBme<!sQPl ; fye;J 
tpOk;.!
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• gPk<K?!hqmiq?!ge<el<!Ngqb!-mr<gtqz<!uQg<gl<!g{<M!gib<s<sz<!
d{<miGl</!
• GtqOviM!wiqs<sz<!
• nkqg!sh<kk<Kme<!-Vlz<!
!
!! Ngqb!GxqG{r<gt<!gi[l</!
 “Gpf<jk<<< !g{<<<<.osuq.oki{<jm!lVk<Kul< << << < << <<”<!lV/w^</sqkl<hvki[hqt<jt!
Fizqe<hc?!oki{<jmbqz<!uVl<!Ofib<gt<!.!9/!
njubiue;!
2/ njmh<he<!
3/ GV!
4/ Hx<X!
5/ hMue<!
6/ uikfijv!
7/ hqk ;jehiu!
8/ rpNyj;Jkehiu!
9/ njhe;jehiu!
!
 “kjiy Neha; njhFjp ;;; – II” d; gb oki{<jmbqz<!uVl<!Ofib<gt<!.!7/!
njubiue;!
2/ oki{<jm!njmh<he<!
3/ oki{<jm!GV!
4/ oki{<jm!Hx<X!
5/ oki{<jm!hMue<!
6/ uikfijv!)ofMfijv*!
7/ hqk ;jehiu (FWehiu)!
!
Ofibqe<!GxqG{r<gt<< < << < << < <;!
• oki{<jm!H{<hm<mkeiz<!uzq!Wx<hmz</!
• oki{<jm!squk<kz<!
• GvOzijs!Gjxkz<!
• Svl<!gib<kz<!
• -Vlz<!
• &s<S!kMlixz<!
• giK!uzq!
• &g<gqzqVf<K!fQi<!uckz<!
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• &g<gjmh<H!
• kjzgek<kz<!
• dmz<!ue<jl!Gjxkz<!
• d{U!ohiVm<gt<!uqPr<g!Lcbijl/!
Lg<Gx<x!OuXhiM< << << < ;!
!! gh! ^<kieligqb! oki{<jmbqz<! npz<! Gx<xlieK! ke<etuqz<!
lqGkqh<hm<M?! utqg<Gx<xk<jkk<! Kj{g<! ogi{<M?! uQg<gl<?! -zSel<! squk<kz<?!
uzq! Lkzqb! GxqG{r<gjt! d{<migg<! %cb! ke<jl! djmbkig!
njlgqxK/!
  “lqgqEl<!GjxbqEl<!Ofib<!osb<Bl<!F~Ozii<!!
!! utqLkzi!w{<{qb!&e<X” 
!!!!!!!!!!!!!!!!!!!!!!!!!!!.kqVg<Gxt<!
!!!!!wEl<! Olx<Ogitqe<! hc! -f<Ofib<! fqjzbqz<! Lg<Gx<xr<gTl<!
ke<eqjzbqz<! kqiqf<K! fqx<gqxK/! ke<eqjzbqz<! sQk! uQiqbl<! nkqgLjmb!
d{Uh<! ohiVm<gt<! )Gtqi<f<k! k{<{Qi<?! sVGgt<! Dxqb! hjpb! k{<{Qi<*!
Ohie<xjugjt! dm<ogit<Tl<! OhiK! -bx<jgbig! njlf<kqVg<gqe<x! npz<!
Gx<xlieK! sQk! uQiqbk<kiz<! K~{<mh<hm<M! oki{<jmbqz<! Okr<gq! fqe<X!
-zSer<gt<!kch<Hl<?!kti<s<sqBl<!d{<migqxK/!
-ju! npZl<?! sQkLl<! OuXhMuke<! giv{k<kqeiz<?! -bx<jg! upq!
fqe<x! utqg<Gx<xl<! Kj{g<! giv{ligq! Oux<Xfqjz! uti<s<sqbjmf<K!
-zSek<jkg<!kihqkh<hMk<Kgqe<xe/!!!
sQk!uQiqbLjmb!d{Uh<ohiVm<gt<!Gtqi<f<k!fQi<?!sVGgt<!Dxqb!
!!!!!!!!!!!!!!!!!!hjpbfQi<!nVf<Kkz<!
!
gh!^<kiek<kqz<!)oki{<jm*!
!
sQk!uQiqbl<!nkqgiqk<kz<!
!
hqk<kl<!ke<etuqz<!nkqgh<hMl<!
!
-zSel<!kch<H?!kti<s<sq!d{<miGl<!
!
uik!Gx<xl<!Oux<Xfqjz!uti<s<sqbjmgqxK!
13 
 
!
uQg<gl<?!-zSel<!squk<kz<?!uzq!-Vg<Gl<!
!
-zSel<!kihqkljmgqxK!
sqk<k!lVk<Ku!Ofib<g{qh<H< < < << < < << < < < ;!
• hq{qbxq!Ljxjl!
• dbqi<!kiKg<gt<!
• dmz<!kiKg<gt<!
• hVur<gt<!
• Jujg!fqzr<gt<!
• dmz<!ue<jl!
• w{<!ujgk<Oki<Ugt<!
• fQi<g<Gxq!
• ofb<Gxq!
!! Olx<Gxqb! giv{qgtqe<! liXhiMgjt! ye<Xme<! ye<X! yh<hqm<Mg<!
g{qg<gh<hMgqxK/!
hq{qbxq!Ljxjl;!
2/ ohixqbiz<!nxqkz<!
3/ Hzeiz<!nxqkz<!
4/ uqeikz<!
-zSekihqkk<kqz<!Ofibitqg<G!gi[l<!GxqG{r<gt</!< < < < < << < < < < << < < < < < !
2/ ohixqbiz<!nxqkz<< << << <!
Okiz<!! .! lqk!ouh<hl<!!
fi!! ! .! Ogijp!Fjvk<kz<!/!liU!hcf<K!gi{z<!
g{<!! ! .! -bz<H!!
&g<G!! .! &g<gjmh<H!/!&g<GfQi<!hib<kz<!!
giK!!! .! gikqz<!uzq!/ giK!lf<kl<!
3/ Hzeiz<!nxqkz<!< << << < !
Sju!!! .! -eqh<H!Sju!okiqkz<!!
ytq!! ! .! -bz<H!!
DX!!! .! ouh<hl<!!
Yjs!!! .! siquv!Ogm<g!-bzijl!/ osuqk<kqxe<!Gjxkz<!
fix<xl<!! .! &g<gqz<!stq!su<U!squf<Kg<gi{z<?!&g<gjmh<H/!!
! !
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4/!uqeikz<<<<;!)Ogm<mxqkz<*< << << < !
lVk<Kue<! ke<! ohixq?!Hzeiz<! Ofibitqbqe<! fqjz! hx<xq!
d{i<f<kjk! OfibitqbqmOli! )n*! nue<! ohx<Oxii<! Sx<xk<kijvg<! ogi{<Om!
nueK!ohbi<?!ubK?!kqj{?!GMl<h!uvziX?!d{U!hpg<gupg<gl<?!Lf<jkb!
Ofibqe<!uvziX?!Ohie<xux<jx!nxqkz<!NGl</!
-jube<xq?!ntju!&zLl<!hq{qjb!nxqb!LcBl</!
ntju!.!21!ujgh<hMl</!weqEl<?!gi{<mz<!gVkz<!djv!!
we<El<!-l<&e<X!ntjubqz<!21!ntjugTl<!nmr<Gl</!!
gi{<mz<!< << << < !
!! Ofibitqbqe<!oki{<jm?!dt<fig<jg!hii<k<kz</!
gVkz<<<<;!
!!Ofibitq! %Xl<! GxqG{r<gtie! d{U?! fQi<! uqPr<g! sqvll<?! Svl<?!
kjzuzq?!-Vlz<?!giKuzq!Lkzqbe/!
djv;!
!! Ofijb!siqbie!Ljxbqz<!g{qk<K!djvk<kz</!
dbqi<kiKg<gt<!)Lg<Gx<xl<*!< < < < < << < < < < << < < < < < ;!
2/ uikl<!<<< !
!!-zSekihqkk<kqz<!gi{h<hMl<!uikk<kqe<!fqjz< < < < < << < < < < << < < < < < ;!
2/ hqvi{e<! ;! hikqh<H!)-Vlz<?!Ogijp!outquvz<?!!
&s<Suqm!sqvll<*!
3/ nhiee<! ;! -bz<H!
4/ uqbiee<! ;! hikqh<H!)d{U!uqPr<Gl<!OhiK!!
oki{<jmbqz<!uzq*!
5/ dkiee<! ;! hikqh<H!)Ohs<osizq!Ge<xz<?!-Vlz<*!
6/ sliee<! ;! hikqh<H!)lx<xuiBg<gjt!gm<Mh<hMk<Kukqz<!sqvll<*!
7/ fige<!! ;! -bz<H!
8/ %i<le!<! ;! -bz<H!
9/ gqVgve<! ;! hikqh<H!)-Vlz<?!&g<gqz<!fQi<!uckz<*!
:/ Okukk<ke<! ;! hikqh<H!)Osil<hjz!d{<mig<Gkz<!
21/ keR<osbe<! ;! .!
3/hqk<kl<< << << <!
!!-zSekihqkk<kqz<!hqk<kk<kqe<!fqjz< < < < << < < < << < < < < ;!
1. nex<hqk<kl<! ! ;! -bz<H!
2. -vR<sghqk<kl<! ;! -bz<H!
3. sikgh<hqk<kl<!! ;! hikqh<H!)d{<[l<!OhiK!oki{<jmbqz<!uzq?!!
dmz<!Osii<U*!
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4. hqvisghqk<kl<! ! ;! -bz<H!
5. NOzisghqk<kl<! ;! -bz<H!
4/!ghl<<<<!
!-zSekihqkk<kqz<!ghk<kqe<!fqjz< < < << < < << < < < ;!
1. nuzl<hgl<! ! ;! hikqh<H!)&s<S!uqm!sqvll<*!
2. gqOzkgl<! ! ;! -bz<H!
3. Ohikgl<! ! ;! -bz<H!
4. kx<hgl<! ! ;! -bz<H!
5. sf<kqgl<! ! ;! -bz<H!
!
dmz<!kiKg<gt<< < << < << < <;!)WP!dmx<gm<Mgt<*!< < << < << < < !
-zSekihqkk<kqz<!dmx<gm<Mgtqe<!fqjz< < < < << < < < << < < < < ;!
2/ sivl<! ! ! ;!! hikqh<H!(dmz<!Osii<U)! !
3/ osf<fQi<!! ! ;!! hikqh<H!(gQpqjl!fQg<gqh<!hii<g<gqe<!!
ouTh<H!dt<tK)! !
4/ D{<! ! ! ;!! hikqh<H!(oki{<jmbqz<!uzq?!!
-zSel<!uQg<gl<!gi{z<)!
5/ ogiPh<H! ! ;!! -bz<H!
6/ we<H! ! ! ;!! -bz<H!
7/ &jt!! ! ;!! -bz<H!
8/ Sg<gqzl<!/ SOvi{qkl<!;!! sqXui<!/ sqXlq!
! ! !
hVugizr<gt<< << << <;!
ohVl<ohiPK! .! he<eqv{<M! kqr<gt</! -h<ohVl<ohiPK! NX! hVu!
gizr<gtigh<! hqiqg<gh<hm<Mt<tK/! -h<hVu! gizr<gtqe<! lix<xk<jkh<! ohiXk<K!
Ofib<gt<! Wx<hmg<%Ml</! weOu?! hVu! gizr<gtqe<! Kj{biz<! hq{qjb!
nxqbuil</!
1. gii<gizl<! ! ;! Nu{q?!Hvm<misq!(Aug to Sep) 
2. %kqi<gizl<!! ! ;! Jh<hsq?!gii<k<kqjg!(Oct to Nov) 
3. Le<heqg<!gizl<! ;! lii<gpq?!jk!(Dec to Jan) 
4. hqe<heqg<!gizl<! ;! lisq?!hr<Geq!(Feb to Mar) 
5. -tOueqz<! ! ;! sqk<kqjv?jugisq!(April to May) 
6. LKOueqz<! ! ;! Neq?!Nc!(June to July) 
!
! !
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Lg<Gx<xr<gTl<?!hVug<gizr<gTl<?!SjugTl</< < < < < < < << < < < < < < << < < < < < < < !
u/!
w{<<<<!
hVug<!gizr<gt<< < << < << < <! Gx<xr<gt<< < << < << < <! Gx<xr<gtqe<!fqjz< < << < << < < ! Sju!
2!
!
gii<gizl<!
!
uikl<! Oux<Xfqjz!
uti<s<sq!
-eqh<H?!Htqh<H?!dh<H!
!
hqk<kl<! ke<eqjz!uti<s<sq!
3!
!
%kqi<gizl<!
!
uikl<! ke<eqjz!uti<s<sq! -eqh<H?!jgh<H?!
Kui<h<H!
!
hqk<kl<! Oux<Xfqjz!
uti<s<sq!
4! Le<heqg<gizl<! hqk<kl<! ke<eqjz!uti<s<sq! -eqh<H?!Htqh<H?!dh<H!
5! hqe<heqg<gizl<! ghl<! ke<eqjz!uti<s<sq! -eqh<H?!Htqh<H?!
Kui<h<H!
6! -tOueqz<!gizl<! ghl<! Oux<Xfqjz!
uti<s<sq!
jgh<H?!Kui<h<H!
7! LKOueqz<!gizl<! uikl<! ke<eqjz!uti<s<sq! -eqh<H!
!
-zSekihqkk<kqz<!hVugizr<gt<< < < << < < << < < <;!
-zSekihqkk<kqz<! hqk<kOkiml<! hikqh<hjmf<K! ke<eqjz! uti<s<sq!
njmf<K! nke<hqe<ei<?! ghlieK! ke<eqjz! uti<s<sq! njmf<K?! Oux<X!
fqjzbqZl<! uti<s<sq! njmf<K! -zSekihqkk<kqe<! GxqG{r<gjt!
d{<mig<gqe<xK/!
weOu?! Le<heq<gizl<!Lkz<!-tOueqz<! gizl<!ujvBt<t! gizl<!
-zSekihqkl<!Okie<Xukx<Giqb!gizr<gtiGl</!(csl<hI!Lkz<!Wh<vz<). 
!
Jujg!fqzr<gt<< << << <;!
1. GxqR<sq!)ljzBl<?!ljz!sii<f<k!-mLl<*.sqOzk<Kl!Ofib<gTg<G!-Vh<hqml<!
2. Lz<jz!)giMl<?!giM!sii<f<k!-mLl<*!.uik!Ofib<gTg<G!-Vh<hqml<!
3. lVkl<!)ubZl<!ubz<!sii<f<k!-mLl<*!.Lg<Gx<xr<gTl<!slh<hMl<!
4. ofb<kz<!)gmZl<!gmz<!sii<f<k!-mLl<*!.uikOfib<!d{<miGl<!
5. hijz!)l{Zl<?l{z<!sii<f<k!-mLl<*!.Lk<Okimr<gTg<G!-Vh<hqml</!
!
dmz<ue<jl< << << < ;!
-K!&e<X!ujgh<hMl</!
nju/!
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1. -bx<jg!ue<jl!
2. osbx<jg!ue<jl!
3. giz!ue<jl!
2/-bx<jg!ue<jl< << << < !
-K!G{r<gt<!&e<xqzqVf<K!-bx<jgbigOu!d{<miukiGl</!
3/osbx<jg!ue<jl< << << < !
-K! -bx<jgbig! d{<mie! dmjz?! Lg<G{r<gTg<G! Wx<xuiX! diqb!
d{U?! osbz<gtiZl<?! dmz<! kiKg<gt<! hikqg<gh<hmi! u{<{l<!
fqjzfqXk<kg<%cb!lVf<KgtiZl<!Oh{qg<!ogit<ukiz<!d{<miukiGl</!
!
4/giz!ue<jl<<< !
-K!hVug<gizr<gtiZl<?!ubkiZl<!d{<miukiGl<!
w{<ujgk<!Oki<U< < << < << < < ;!
  ‘fich<hiqsl<!fifqxl<!olipquqpq!!
!! lzl<!lk<kqvlqju!lVk<KuviBkl<’!
ohiVt<;!
1. fic!
2. ^<hiqsl<!
3. fi!
4. fqxl<!
5. olipq!
6. uqpq!
7. lzl<!
8. &k<kqvl<!
!
u/w{<!<<< w{<ujgk<!Oki<Ugtqe<!-bg<g!fqjz< < < < << < < < << < < < < ! -zSe!kilqkk<kqz<!d{<miGl<!< < < << < < << < < <
liXhm<m!fqjz<<< !
2!
/!
fic;!
 utq?!npz<?!Jbl<?!gzh<H?!Lg<Gx<xl<!
ficgtqe<!ke<!fjm?!Hxfjm?!
-jtk<kz<?!gkqk<kz<?!Gkqk<kz<?!
Kt<tz<?!nPf<kz<?!hMk<kz<?!gzk<kz<?!
Le<Ofig<G?!hqe<Ofig<G?!hg<g!Ofig<G?!
Spzz<!Ngqb!Gxqgjt!nxqbzil</!
 hqk<kghl<!
 gh!hqk<kl<!
Olx<ogi{<m!fic!fjmgt<!
-zSekihqk!Ofibqz<!gi[l</!
3!
/!
^<hiqsl<;!
)okim<Mh<hii<k<kz<*!
 $mibqVk<kz<?!ogikqk<kqVk<kz<?!
 -zSekihqkk<kqz<!Svl<!
gi[l<!
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Gtqi<f<kqVk<kz<?!sqz!-mr<gtqz<!
$migUl<?!Lx<Xl<!sqz<zqm<cVk<kz<?!
uqbi<k<kqVk<kz<?!lvk<kqVk<kz<?!
hqShqSk<kz<?!Okiz<!ouch<H?!lbqi<!
kck<kz<?!dkqi<kz<?!sqzqi<k<kz<?!dmz<!
SvSvk<kz<?!kck<kz<?!hjmgT{<.!
mikz<?!Oklz<!ohxz<?!gm<cgt<?!osixq?!
sqvr<G?!H{<?!Hjv?!Hx<Xgt<?!
!
 uQg<gl<!Lkzqbju!oke<hMkz<?!Okgl<!
-jtk<kz<!)n*!hVk<kqVk<kz<!Lkzqb!
GxqG{r<gjt!Nvib<ukil</!
 gPk<kqe<!nVgqz<!dt<t!
 fq{g<Ogitr<gtqz<!uQg<gl<!
-Vg<Gl</!
4!
/!
fi;!
 uik?!hqk<k?!Jb?!fqxl<?!hzfqxl<?!
lisx<xqVk<kz<?!lih<hcf<kqVk<kz<?!uib<!
fQi<!ohVgz<?!ux{<cVk<kz<?!
gXk<kqVk<kz<?!uib<!H{<{ibqVk<kz<?!
hqtU?!kch<H!gi{z<?!Yvr<gtqz<!
ht<tl<Ohiz<!hkqf<kqVk<kz<?!hx<gtqe<!
fqjzjl?!wbqXgtqe<!fqjzjl?!Sju!
nxqkz<?!Ohs<sqe<!fqjzjl?!fiju!
outqOb!fQm<ceiz<!yV!Hxligs<!
sib<f<kqVk<kz<?!uib<!Ogi{zib<!
-Vk<kz<!Ngqb!GxqG{r<gjtg<!
gueqh<hkiGl</!
 -zSekihqkk<kqz<!fi!
ouTk<K!gi[l<?!Ogijp!
ou{<jl!fqxk<kqz<!
outqh<hMl<?!Ohs<osizq!
kip<f<K!gi{h<!hMl</!
5!
/!
fqxl<;!
 dmz<!hiqOsikjebqz<!uik?!hqk<k?!
Jb!fqxr<gt<?!gzh<H!fqxl<!)gXk<kz<?!
lR<stqk<kz<?!squk<kz<?!fQzlikz<?!
outqvz<*!Lgl<!squk<kz<?!outqvz<?!
uqpqBl<!hz<Zl<!gXk<kz<!Lkzqb!
Gxqgjt!nxqkzil</!
 -zSekihqkk<kqz<!
oki{<jm?!-zSel<!
squf<Kg<!gi[l</!
6!
/!
olipq;!)Yjs*!
 Ofibitq!OhSl<!ohiPK!
 -zSekihqkk<kqz<!Ohs<osizq!
kip<f<K?!Gvz<!gl<lZme<!
gi[l</!
!  dvk<k!yzq?!sl!yzq?!Gvx<gl<lqb!
Ohs<S?!kip<f<kyzq?!sqiqk<kz<?!hqkx<xz<?!
Gpxz<?!sl<hf<klqz<zik!Ohs<S?!Ohsik!
!
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OhiK!ghk<OkiM!&s<Suqmz<?!ghk<OkiM!
%cb!Ohs<S?!&s<Sk<!kir<gq!kir<gq!
uqMukigqb!FjvbQvzqe<!yzq!Lkzqb!
GxqG{r<gjt!nxqkzil</!
7!
/!
uqpq;!)g{<*!
 g{<{qe<!fqxl<?!g{<!gzr<gz<?!
fQi<uckz<?!uQr<gz<?!g{<!hii<jubqe<!
fqjzjl?!g{<!Ofib<gt<!
oki{<[~x<xijxBl<!hx<xq!Nvib<kzil</!
!
 -zSekihqkk<kqz<!uqpq!
squf<K!-Vg<Gl</!
8!
/!
lzl<;!
 lzk<kqe<!fqxl<?!ke<jl?!fix<xl<?!
lzk<Kme<!sQp<?!-vk<kl<!-ju!gzf<K!
Ohikz<?!lzl<!Ohikzigqb!
G{r<gjtBl<!gueqh<hkiGl</!
!
 -zSekihqkk<kqz<!
lzg<gm<M!-Vg<Gl</!
9!
/!
sqXfQi<;!
 fqxl<?!l{l<?!gzh<H?!Fjv?!wR<sz<!
Ljx?!fqjx?!sk<K!)Sju*!-jugjt!
Nvib<ukiGl</!
 -zSekihqkk<kqz<!sqXfQi<!
lR<stqk<Kl<?!sqXk<Kl<!
-xr<Gkz<!gi{h<hMl</!
!
ofb<g<Gxq< << << < !
ofb<g<Gxqbqe<!sqxh<H< < < << < < << < < < ;!
“Jg<Gxq!ogiMum!uieqp!zli<f<Okii<< < < << < < << < < <!
jgg<Gxq!okiqk<k!fr<gmUjtk<!Kkqk<Ok< < < < << < < < << < < < < !
olb<g<Gxq!fqxf<oki{q!uqpqfi!-Vlzl<!< < < << < < << < < < !
jgg<Gxq!LPuK~ur<!gx<xii<!kl<lqEl<!< < < < < << < < < < << < < < < < !
ohib<g<Gxq!olb<g<Gxq!HgZ!olui<g<Gl<< < < < < < << < < < < < << < < < < < <!
ofb<g<Gxq!nkje!-f<fq{qzk<!< < < << < < << < < < Kjvh<hil<< << << <”/!
!Ofib<!fimz<!Ofib<!Lkz<!fimz<!higl<.2!
hg<gl<!w{<!.3:9!
w{<o{b<!uqm<M!hii<g<Gl<!fQiqe<!uqkq;< < < < < < Q << < < < < < Q << < < < < < Q < !
  “fqxg<Gxqg<!Gjvk<k!fqVlie!fQiqe<!< < < Q << < < Q << < < Q < !
!! sqxg<g!ou{<o{b<!Obii<!sqXKtq!fMuqMk<< < < < << < < < << < < < <!
!! oke<Xxk<!kqVf<okizq!Wgikjlk<kkq< < < << < < << < < < !
!! eqe<xkqujz!Ohil<!ofxquqpqbxqUl<< < << < << < <!
!! ose<xK!<<< HgZR<!osb<kqjb!B{Ov/< << << < ” 
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ohiVt<;<<< !
fQi<! fqxg<Gxqbiz<! Ofijbg<! g{<M! hqck<kx<! ohiVm<Ms<!
osiz<zqbqVg<gqe<x! uqkq! ohiVf<kqb! sqXfQiqz<! yV! sqxqb! Ktq! w{<o{jb!
fMuqz<! jgbjsuqeiz<! w{<o{b<k<! Ktq! sqkxilz<! uqm<M! oub<bqzieK!
nf<fQiqz<! hMl<hc! kqxf<K?! gix<xieK! nkqz<! uQsq! nf<k! w{<o{b<k<! Ktq!
Nmikhc! juk<K?! ns<sqXfQiqz<! uqmh<hm<cVg<gqe<x! w{<o{b<k<! KtqbieK!
osz<Zgqe<x! upqbqz<! g{<{xqjuBl<?! dbqvxqjuBl<! osZk<kq?! nk<Ktq!
okiquqg<Gl<!Ofib<!uqtg<gk<jk!fQ!okiqf<K!ogit<uibig/!
!
  “nvoue!fQ{<ceQ <Q <Q < 0Ok!uikl<<<<”!
  “Npq!Ohiz<!hvuqe<!n< << << < 0Ok!hqk<kl<< << << <”!
  “Lk<okik<K!fqx<gqe<!olipquoke<ghOl< < < < << < < < << < < < < ”/!
!
ohiVt<;<<< !
hil<H!Ohiz<!fQ{<miz<!.!uik!fQi<!
Olikqvl<!Ohiz<!hvuqeiz<!.!hqk<k!fQi<!
Lk<Kh<Ohiz<!fqx<Glibqe<!nK!.!gh!fQi<!we!nxqbzil</!
-zSekihqkk<kqz<! ghk<kqx<Giqb! nz<zK! hqk<kk<kqx<Giqb! nz<zK! okif<k!
Okimk<kqx<Giqb!ofb<g<GxqObi!nz<zK!-bz<higOui!-Vg<Gl</!
hqk<kgh!fic<<< ;!
  “h{<hie!hqk<kk<kqz<!Osk<Kl!fic< < < < << < < < << < < < < !
hiqsqk<ki!zk<kqSv!lqjth<H!=jt< < << < << < < ” 
(Ofib<fimz<!Ofib<Lkeimz<!kqvm<M!higl<!.2*!
.skg!fic!!
hg<gl<!w{<!.296!
ghhqk<k!fic<<< ;!
“-mlie!Osk<Klk<kqz<!hqk<kfic!< < < << < < << < < < !
wPf<k[gqz<!uqmLmOe!uQg<g!L{<mil<?!< < Q < < << < Q < < << < Q < < < !
kqmlie!Gtqi<!gib<s<sz<!lR<st<!OfiUf<!< < < < < < << < < < < < << < < < < < < !
Okgk<kq!Zjts<szqjth<!hqVlz<!uif<kq!< < < < << < < < << < < < < !
!!!!!uqmlie!ofR<sjmh<H!Suisl<!uqg<gz<< < < < << < < < << < < < <”!
(Ofib<fimz<!Ofib<Lkeimz<!kqvm<M!higl<!.2*!
.skg!fic!!
hg<gl<!w{<!.298!
!
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lVk<Kul<< << << <;!
  “Ofib<fic!Ofib<Lk!eic!bKk{qg<Gl<?< < < << < < << < < < !
!! uib<fic!uib<h<hs<!osbz<< < < < << < < < << < < < <”/!
!! ! ! ! ! .!kqVg<Gxt<!
!! we<hkx<gq{r<g?! d{uikq! osbz<gtiz<! d{<mil<! Ofibqje! nxqBl<!
ohiVm<M?! Ofib<! nxqkx<gie! fimz<! upqbqjeg<! %XuKl<! n0K! d{U!
osbz<gtqe<! lqGkq?! Gjxuiz<! utq?! npz<?! Jbl<! -l<&e<xqz<! ye<OxEl<?!
-v{<OmEl<?! &e<OxEl<! lqGf<K! nz<zK! Gjxf<K! hq{qg<gh<hMlijgbiz<?!
hq{qg<gh<hm<m! Gx<xl<! biK@! nkx<G! Lke<jlbigbqVf<kK! wK@! nkjek<!
k{qh<hkx<G!upq!wK@!we!fiMkOz!lVk<Kueqe<!fx<osbzil</!
!! “dx<xi!etUl<!hq{qbtUr<!gizLr<< < < << < < << < < <!
!! gx<xie<!gVkqs<!osbz<< < < << < < << < < <”/!
. kqVg<Gxt<!
!! we<hkeiz<?! Ofibqee<! njmf<k! Gx<x! OuXhiMgtqe<! lqGkz<! Gjxkz<!
ntjuBl<! nkeiz<! OfiBx<xie<! ohx<x! Ofibqe<! ntjuBl<! )kQVl<! kQvioke*!
nxqf<khqe<?! Ofibqe<! giz! ntju! nxqf<K?! sqf<kqk<K?! kGf<k! lVk<Kul<! HiquK!
nusqbl</!
lVk<Ku!upqLjx<<< ;!
2/ ke<eqjz!uti<s<sqbjmf<k!Gx<xr<gjts<!slh<hMk<k!Ou{<Ml</!
3/ ue<jl! -pf<k! dmx<gm<Mgjt! ue<jl! njmbs<! osb<b! lVf<ktqg<g!
Ou{<Ml</!
4/ Ofib<g<gie!lVf<Kgjt!upr<g!Ou{<Ml<!
lVk<Ku!nxqUjv!;<<< !
hk<kqbl<;!
“hk<kqbk<kqeiOz!hzE{<mil<!lVf<K!< < < < << < < < << < < < < !
hk<kqbr<gt<!Ohieiz<!hze<!OhiGl<!< < < < < << < < < < << < < < < < .!hk<kqbk<kqz<!< < << < << < < !
hk<kqbOl!oux<xqkVl<!h{<cki<g<G!Nkzqeiz<< < < < < < << < < < < < << < < < < < <!
hk<kqbOl!dk<kq!obe<X!hii<< < < << < < << < < <”/! ! ! ! !
!! ! ! ! ! ! .!)Okjvbi<*!
lVf<K{<[l<! gizr<gtqz<! Ofibitqbqe<! Ofibqe<! ke<jl! ohiVk<K!
d{U!lx<Xl<!osbz<gtqz<!hk<kqbl<!NGl</!
d{<{!Ou{<cbju< << << < ;!
• LVr<jgh<hqR<S!
• gk<kiqh<hqR<S!
• g{<mr<gk<kqiq!
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• Ohb<h<Hmz<!
• hQi<g<gl<!hqR<S!
• gQjv! ujggtqz<! K~Kujt?! giqsijz?! l{qk<kg<gitq?!
ohie<eir<g{<{q/!
• =Vt<tq!
• Yluz<zq!-jz!
• H,{<Mk<Oke<!
• nk<kqg<gib<!!-jugjt!Osi<k<Kg<!ogit<tzil</!
kuqi<g<g!Ou{<cbju< < << < << < < ;!
• wt<!
• ogit<T!
• jgh<H?!Htqh<H!SjuBt<t!d{Uh<!ohiVm<gt<!
• ngk<kq!gQjv!
• higx<gib<!
• lQe<!
• gVuiM!
• Ogipq!)out<jt*!
• -eqh<H!h{<mr<gt<!
• Gtqi<f<k!k{<{Qi<!
• hS!OliI!
• Htqk<k!kbqi<!
• Okr<gib<!
• osbx<jg!Gtqi<hier<gt<!
• J^<gqiQl<!
• sig<ozm<!
osbz<gt<< << << <;!
• Gtqi<f<k!fQiqz<!kjz!LPgg<!%miK/!
• Gtqi<f<k!kjvbqz<!nkqgl<!=MhMkz<!%miK/!
• ouKouKh<hie! fQiqz<! dh<Hh<! Ohim<M! fQvieK! oki{<jmbqz<! hMl<hc!
ogih<htqg<g!Ou{<Ml</!
• kqeLl<!-VLjx!hz<!Kzg<g!Ou{<Ml</!
• ouf<fQjvh<!hVg!Ou{<Ml</!
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MODERN ASPECT 
 
ANATOMY OF TONSIL: 
• Tonsils are collections of lymphatic tissue facing into the aerodigestive 
tract. It is located in the wall of the pharynx. It belongs to the lymphatic 
system and immune system. It helps to protect the body from upper 
respiratory tract infection. 
• The tonsils begin developing early in the third month of foetal life. They 
arise from the endoderm lining, the second pharyngeal pouch, and  the 
mesoderm of the second pharyngeal membrane and adjacent regions of the 
first and second arches 
• The epithelium of the second pouch proliferates to form solid endodermal 
buds, growing into the underlying mesoderm. These buds give rise to 
tonsillar stroma. 
• Central cells of the buds later die and slough, converting the solid buds 
into hollow tonsillar crypts, which are infiltrated by lymphoid tissue. 
• Both right and left tonsils form part of the circumpharyngeal lymphoid 
ring. The size of the tonsil varies according to the age, individuality and 
pathologic status 
• At the fifth or sixth year of life, the tonsils rapidly increase in size at 
puberty. At puberty, the tonsils measure 20-25 mm in vertical and 10-15 
mm in traverse diameters. 
BED OF THE TONSIL: 
Bed of the tonsil comprises of loose areolar tissue, pharyngobasilar fascia, 
superior constrictor muscle. 
VASCULAR SUPPLY OF TONSIL: 
The arterial supply of the tonsils is derived from the following arteries: 
1. Tonsillar artery 
2. Ascending pharyngeal artery 
3. Tonsillar branch of  the facial artery 
4. Dorsal lingual branch of the lingual artery 
5. Ascending palatine branches of the facial artery 
Venous blood drains through a peritonsillar plexus. The plexus drains 
into the lingual and pharyngeal veins, which in turn drain into the 
internal jugular vein. 
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NERVE SUPPLY OF TONSIL: 
• The tonsils are innervated through tonsillar branches of the maxillary 
nerve and the glossopharyngeal nerve. 
LYMPHATIC SUPPLY OF TONSIL: 
• Tonsils do not  posses afferent lymphatics. Efferent lymphatics drain 
directly to the jugulo digastric node and indirectly through the 
retropharyngeal lymph nodes. 
NATURAL VARIANTS OF TONSIL: 
• The tonsil is more active in childhood and gradually becomes smaller 
during puberty. 
• Its appearance may give a misleading estimate of its size. 
• Some tonsils appear to lie mostly on the surface of the throat, with a 
shallow tonsillar fossa others appear to be mostly buried in a deep tonsillar 
fossa. 
PATHOPHYSIOLOGIC VARIANTS OF TONSIL: 
• Tonsillar involution begins at puberty; by old age, only a little tonsillar 
tissue remains. Tonsillar crypts may contain desquamated epithelial debris 
and cells. Usually, this debris is cleared from the crypts. Rarely, the debris 
may remain in the crypts and become hardened and yellow in appearance. 
• The tonsil plays important role especially in young children. 
Difference between Tonsils and Adenoid: 
S.NO             TONSILS                   ADENOID 
   1 Tonsils are paired Adenoid is single 
   2 Situated in Oropharynx 
Situated on the roof and post,wall of 
nasopharynx.  
   3 
Covering epithelium  is 
Stratified squamous 
Covering epithelium of adenoid is Ciliated 
columnar. 
   4 
In tonsils the crypts are present 
on the medial surface. 
In adenoid the longitudinal furrows are 
present on the ventral surface 
   5 
In tonsils the capsule is present 
on the lateral surface. 
In adenoid ,there is no capsule at all 
 
  
 TYPES OF TONSILS :
Tonsils are majorly classified in to 4 types
• PHARYNGEAL TONSIL
• PALATINE TONSIL
• TUBAL TONSIL
• LINGUAL TONSIL
These four types of tonsils are anatomically connected and it makes 
“Waldeyer’s Ring”. 
.WALDEYER’S RING:
An interrupted circle of protective lymphoid tissue at the upper ends of the  
respiratory and alimentary tracts
25 
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• The palatine tonsils, nasopharyngeal tonsil (adenoid) and lingual tonsil 
constitute the major part of Waldeyer ring or nasal associated lymphoid 
tissue (NALT) with the tubal tonsils and the lateral pharyngeal bands as 
less prominent  component. 
• A ring composed of NALT at the beginning of food and air passage, 
produces T and B lymphocytes which acts as local defence. Waldeyers 
ring consists of lymphoid tissue that surrounds the openings of the oral and 
nasal cavities into the pharynx. 
• The most important aggregation are the right and left palatine tonsils, 
usually refers to simply as the Tonsils. 
• Posteriorly, and above there is the pharyngeal tonsil; laterally and above 
there are the tubal tonsils, and inferiorly that is the lingual tonsil over the 
posterior part of the dorsum of the tongue. 
 
NORMAL FUNCTION OF TONSILS: 
• Tonsils are the immune’s first line of defense against ingested and inhaled 
foreign pathogens. 
• Tonsils have on their surface specialized antigen capture cells called M 
cells that allow for the uptake of antigens produced by pathogens. These M 
cells then alert the underlying B cells T cells in the tonsils and the immune 
response is stimulated. 
• Lymphoid tissue of Waldeyer ring is most immunologically active 
between 4and 10 years of age, but decrease after puberty. Deep crevices 
within tonsillar tissue form tonsillar crypts that are lined with squamous 
epithelium but have a concentration of lymphocytes at their bases. 
 -Nelson Text Book of Pediatrics 
    Page No:1756 
DEFINITION OF TONSILLITIS 
  Tonsillitis is the inflammation of the tonsils and usually occurs secondary to 
viral (a) bacterial influenza and staphylococci. On examination, the tonsils are 
enlarged and inflamed. Presence of follicles over the tonsils indicates bacterial 
infection (usually streptococcal).In addition there may be tender jugulodigastric 
lymph nodes. 
 -Achar’sTextbookofPediatrics 
(4th Edition) 
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ETIOLOGIC AGENTS: 
Common pathogen:       
• Group A Beta Hemolytic streptococci 
 
Less common pathogens: 
• Non group A S treptococcus 
• Staphylococcus aureus 
• Hemophilus influenza 
 
Differentiating 
Features 
Viral origin of 
Tonsillitis 
Bacterial origin of 
Tonsillitis 
Duration Of  Illness 
Entire illness lasts for 5 
days 
Lasts for 2 weeks 
 
Sore Throat 
Pain occurs initially  in  
pharynx . 
Pain occurs initially in  
tonsils after 12 to 24 hours 
with constitutional 
symptoms . 
Fever 
 
Fever reaches peak by 
second or third day. 
Fever may not be noted 
upto first day. Later, the 
body temperature rise upto 
40 C and continues for 4 
days. 
Cervical Lymph 
Nodes 
Firm and enlarged lymph 
nodes 
Anterior cervical lymph 
node enlarged 
 
TYPES OF TONSILLITIS 
  There are three main types of tonsillitis:        
Acute Tonsillitis Bacterial or viral (75% )origin 
Sub Acute Tonsillitis It can last between 3 weeks to 3 months. 
Caused by the bacterium Actinomyces. 
Chronic Tonsillitis If not treated it can last for long periods, is 
almost always bacterial origin. 
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ACUTE TONSILLITIS 
Definition:  
  Acute inflammatory condition of the faucial tonsils often caused by 
Streptococcus, Staphylococcus, Hemophilus influenza or specific infections like 
diphtheria. 
 
TYPES OF ACUTE TONSILLITIS 
• Acute Non specific tonsillitis 
• Acute specific tonsillitis  
 
ACUTE NON-SPECIFIC TONSILLITIS: 
 Definition: 
              Acute inflammatory condition of the faucial tonsil which may involve the 
mucosa, crypts, follicles and tonsillar parenchyma. 
  Causative Agents :  
• Viral:    Initially starts with viral infection which is followed by secondary 
bacterial infection.  
Viruses commonly isolated include influenza, para-influenza, adeno virus 
and rhino virus. 
• Bacterial:   Streptococcus, Staphylococcus, Hemophilus influenza. 
 
 PATHOGENESIS 
• Usually it starts in childhood when there is a low immune status developed 
due to reduction in maternal immunity and an inadequately developed 
child’s own immunity which  makes the child more prone to for infection 
involving the waldeyer’s ring and helps in future production of antibodies 
as the firstline defense mechanism. 
 
CLASSIFICATION OF ACUTE NON-SPECIFIC TONSILLITIS: 
• Depending on the progress of the disease, this can be classified further into 
the following types such as 
1.Catarrhal tonsillitis 
2.Cryptic tonsillitis 
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3.Acutefollicular tonsillitis 
4.Acute membranous tonsillitis 
5.Acute parenchymal tonsillitis 
6.Peritonsillitis or peritonsillar abscess 
CLINICAL FEATURES OF ACUTE TONSILLITIS: 
Symptoms: 
• Fever which is always high grade 
• Generalised malaise and bodyache 
• Odynophagia (pain during swallowing) 
• Dry cough 
• Sore throat 
 
Signs : 
• Dry tongue 
• Erythematous enlarged tonsil 
• Palatine petechiae 
• Enlargement of the jugulodigastric 
lymph  nodes 
 
DIFFERENTIAL DIAGNOSIS OF ACUTE TONSILLITIS: 
• Diptheria 
• Vincent’s angina 
• Agranulocytosis 
• Infectious mononucleosis 
• Adenoid facies or long face syndrome. 
 
Adenoid facies or long face syndrome. 
  It is long, open-mouthed, face of children with adenoid hypertrophy. The 
mouth is always open upper airway congestion has made patients obligatory mouth 
breathers. The most common presenting symptoms are chronic mouth breathing and 
snoring. The most dangerous symptom is sleep apnea. 
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CHRONIC TONSILLITIS 
Definition 
It is the chronic inflammation of the palatine (faucial) tonsils which 
occurs as a result of repeated attacks of acute tonsillitis or due to inadequately 
resolved acute tonsillitis. 
 
Etiopathogenesis 
• The most frequent etiology agent is Beta haemolytic streptococcus. 
• It follows as a complication of acute tonsillitis. Pathologically 
micro abscesses walled off by fibrous tissue have been seen in 
lymphoid follicles of tonsils. 
• It may be a subclinical infection of tonsils without an acute attack. 
• Mostly affects children and young adults. 
• Predisposing factor may be chronic infection in sinuses or teeth. 
 
CLINICO PATHOLOGICAL TYPES OF CHRONIC TONSILLITIS 
1. Chronic follicular tonsillitis 
2. Chronic parenchymatous tonsillitis 
 
GRADING OF CHRONIC PARENCHYMATOUS TYPE OF TONSILLITIS:  
  In chronic parenchymatous type of tonsillitis, the tonsils are enlarged and may 
be graded into 4 types depending on this size. 
• Grade I: Tonsils are congested but are located within the tonsillar fossa 
• Grade II: Tonsils hypertrophies till the brim of the tonsillar fossa 
• Grade III: Tonsillar hypertrophy extends beyond the pillars but does not 
touch each other 
• Grade IV: The tonsils are in contact with each other (Kissing tonsils) 
causing respiratory and deglutition problems. 
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3. Chronic fibrotic tonsillitis: 
CLINICAL FEATURES OF CHRONIC TONSILLITIS: 
Symptoms 
• Sore throat (recurrent attacks three to four times a year) 
• Cough 
• Hawking 
• Halitosis 
• Bad taste in the mouth due to pus in 
crypts 
• Thick speech 
• Difficulty in swallowing 
• Sleep apneic episodes 
• Acute exacerbations produce symptoms similar to acute tonsillitis. 
Signs 
• Thin pale child without the usual healthy sparkle and the presence of dark 
circle under the eyes 
• Local signs in the throat are bands of congestion down the free margins of 
flush of the anterior pillars of tonsils whose crypts on pressure. 
• The size of tonsils is often small and buried in chronic infection, due to 
fibrosis. 
• The cervical glands at the angle of the mandible become persistently 
enlarged. 
DIFFERENTIAL DIAGNOSIS OF CHRONIC TONSILLITIS: 
• Peritonsillar abscess (Quinsy) 
• Peritonsillar cellulitis (Peritonsillitis) 
• Parapharyngeal abscess 
• Parapharyngeal neoplasm 
• Tonsillar Diphtheria: 
   The faucial (pharyngeal) form is most common. It is manifested with sore 
throat, malaise and mild to moderate fever. Initially there is mild pharyngeal 
erythema, usually followed by progressive formation of whitish tonsillar exudate, 
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which  is over a period of 24 to 48 hours changes into a greyish membrane that is 
tightly adherent and bleeds on an attempted removal. Cervical adenopathy and soft 
tissue oedema result in typical bull neck appearance and stridor. 
 
COMPLICATION OF TONSILLITIS: 
LOCAL COMPLICATION 
• Peritonsillar abscess(Quinsy) 
• Parapharyngeal abscess 
• Intratonsillar abscess 
• Tonsillolith 
• Tonsillar cyst 
• Recurrent tonsillitis 
• Crypt formation 
• Hypertrophy of the tonsil 
 
SYSTEMIC COMPLICATION 
• Focus of infection in renal failure, acute glomerulonephritis, eye and 
skin disorders. 
• Rheumatic fever-Rare condition that causes widespread inflammation 
throughout the body. 
• Lemierre’s syndrome - Rare condition bacteria spread from throat to 
major veins and cause infection. 
• Septicemia 
 
DIAGNOSIS 
DIAGNOSIS OF ACUTE TONSILLITIS: 
The signs necessary for the diagnosis of acute tonsillitis are,  
• Congested and oedematous tonsils seen in Acute  catarrhal tonsillitis. 
• Tonsils may be diffusely swollen appearance in Acute parenchymatous 
tonsillitis. 
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• Crypts can be seen filled with pus with swollen follicles in Acute 
follicular tonsillitis 
• When the pus from the crypts coalesce it gives a membranous appearance 
and is often seen in Acute membranous tonsillitis. 
 
DIAGNOSIS OF CHRONIC TONSILLITIS: 
  Four cardinal signs are necessary for the diagnosis of chronic tonsillitis.  
       They are, 
• Persistent congestion of the anterior pillars 
• Positive tonsillar squeeze (Ervin-Moore sign). 
   A tongue depressor is placed on the anterior pillar and pressed against the 
tonsil to squeeze. 
   If purulent yellowish cheesy discharge escapes out from the crypts, the 
test is positive. 
• The jugulodigastric lymph node on either sides are usually enlarged but 
non tender. 
• In chronic parenchymatous type of tonsillitis, the tonsils are enlarged. 
 
 TREATMENT OF TONSILLITIS 
• Conservative-General health, diet and treatment of co-existing infection 
of tooth, nose and sinuses. Treatment of acute exacerbations as in acute 
tonsillitis 
• Surgical-Tonsillectomy 
 
Tonsillectomy 
Types 
• Dissection method 
• Cryosurgery 
• Monopolar cautery assisted tonsillectomy 
• Bipolar cautery assisted tonsillectomy with or without aid of microscope 
• Laser assisted tonsillectomy 
• Coblation tonsillectomy(Radiofrequency ablation) 
• Harmonic scalpel assisted tonsillectomy 
• Guillotine tonsillectomy 
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Contraindications of tonsillectomy: (ABCDEF) 
• Active infection or active exacerbation, Aneurysm of internal carotid 
artery, Age below three years. 
• Bleeding and clotting disorders 
• Cervical spine pathology  
• Diphtheritic tonsillitis,  
• Drugs : Patients under aspirin, oral contraceptives 
• Endemic of polio 
• Failure to control systemic diseases like hypertension, diabetes, bronchial 
asthma. 
 
PREVENTION OF TONSILLITIS: 
• Tonsillectomy can prevent tonsillitis, but is only recommended in select 
circumstances. 
• Avoid direct contact with infected persons. Tonsillitis are spread by 
droplet transmission, droplet precautions must be taken by means of 
prevention. 
• Take enough liquids to keep the body hydrated. 
• Eat nutritional diet includes fruits, vegetables soups. 
• Should not exposed to passive smoking 
• Should not eat unhygienic Food and drinking contaminated water 
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4. MATERIALS AND METHODS 
CLINICAL STUDIES 
 
  After finishing the studies 40 cases were selected from the OPD and 
IPD of Kuzhanthai Maruthuvam Department. The patients were treated with the 
trail drug Sugantha Malli Chooranam and observed for prognosis clinically. 
 
STUDY DESIGN AND CONDUCT OF THE STUDY: 
Study Type An observational clinical study 
Study Place 
Post graduate Kuzhanthai Maruthuvam OPD and IPD 
Government Siddha Medical College,Palayamkottai. 
Study Period: 24 months 
Sample Size: 40 Patients ( 20 OP + 20 IP) 
The sample consists all patients 5-12 years age group fulfilling all the inclusion and 
exclusion criteria. 
 
STUDY PARTICIPANTS: 
INCLUSION CRITERIA 
 Age 5 to 12 years 
 Sex - Male and female children 
 Throat pain 
 Dysphagia 
 Hoarseness of voice 
 Enlarged tonsils 
 Referred pain in the Ear 
 Malaise 
 Mild fever with tonsillitis 
 
EXCLUSION CRITERIA 
 Congenital anomalies of pharynx 
 Known case of Pulmonary Tuberculosis. 
 Physiological hyperplasia of lymphoid follicles 
 Malignancy 
 Tonsillitis which have indication for surgery 
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WITHDRAWAL CRITERIA 
 The drug not responding to the condition. 
 Intolerance to the drug and development of adverse reactions during drug trail. 
 Patient turned unwilling to continue in the course of clinical trail. 
 Occurrence of any serious illness 
TERMINATION CRITERIA 
 Not reporting subsequently 
 Voluntary termination 
TESTS AND ASSESMENTS 
 Clinical assessment 
 Siddha methodological assessment 
 Laboratory Investigation Imaging assessment 
CLINICAL ASSESSMENT: 
 Throat pain 
 Dysphagia 
 Hoarseness of voice 
 Enlarged tonsils 
 Malaise 
 Mild fever with tonsillitis 
 Referred pain in ear 
 Oedema of uvula and congestion 
 
SIDDHA TESTS AND ASSESSMENTS: 
I. UDAL KATTUKAL 
Saram 
Senner 
Oonn 
Kozhuppu 
Enbu 
Moolai 
Sukkilam/suronitham 
II ENVAGAI THERVU 
Naadi 
Sparisam 
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Naa 
Niram 
Mozhi 
Vizhi 
Malam 
Moothiram 
II - NEERKURI 
IV-NEIKURI 
INVESTIGATION: 
• Blood :   TC, DC, ESR, HB, Total RBC Count, Absolute Eosinophil   
Count 
• Urine :   Albumin, Sugar, Deposits 
• Motion :    Ova, cyst 
SPECIAL INVESTIGATIONS: 
• Throat swab culture (group A haemolytic streptococcus) 
• ASO TITRE  
METHODOLOGY OF TREATMENT: 
Study Enrollment: 
  Patient reporting at the OPD associated with Clinical Features of 
• Throat pain 
• Difficulty in swallowing 
• Difficulty in Speaking 
• Mild fever with tonsillitis 
• General tiredness 
• Pain in the Ear 
  are choosen for enrollment based on the inclusion criteria 
The patient’s parents/guardian who are informed (Form IV) about the 
study trial drug. Post outcomes and the objectives of the study in the language 
and terms understandable to them and the informed consent would be obtained in 
writing form them in the consent form (Form IV) 
 
  
38 
 
 
CONDUCT OF THE STUDY: 
The trial drug will be given in the OPD Department of Kuzhanthai 
Maruthuvam GSMC Palayamkottai. The patients will be asked to have a regular 
follow up in the OP Department once in 2 days. In each and every visit the 
clinical assessment will be recorded in the prescribed proforma, The laboratory 
investigation will be done before and after treatment and recorded in the 
prescribed format. 
DATA MANAGEMENT: 
After enrolling the patients in the study, a separate file for each patient 
will be maintained and all forms will be kept in the file. Whenever the patient 
visits OPD during the study period, necessary entires will be made at the 
assessment forms. Data recordings and adverse events, of any, will be monitored 
by the Head of the Department and Pharmacovigilance committee. 
OUTCOME: 
Primary Outcome: 
Primary outcome is mainly assessed by comparing the reduction in clinical 
symptoms are recurrence before and after treatment. 
Secondary Outcome: 
Secondary outcome is assessed by comparing the safety Parameters before and 
after treatment 
PROGNOSTIC CRITERIA 
GRADE I : Showed good improvement 
GRADE II : Symptoms moderately reduced 
GRADE III : Symptoms slightly reduced 
GRADE IV : No improvement 
ETHICAL ISSUES: 
1. To prevent any infection while collecting blood samples from the patient, only 
disposable syringes, disposable gloves with proper sterilization of laboratory 
equipments will be used. 
2. There will be no infringement on the rights of patient. No other external or 
internal medicines will be used other than the trail drug in the treatment course 
of Lasunathabitham there will be no infringement on the rights of the patient. 
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3. The data collected from the patient’s parents or guardian will be kept 
confidential 
4. The patient’s parents or guardian will be informed about the disease and other 
details of the treatment. 
5. After obtaining the written consent of the patient’s Parents or guardian ( 
through consent form in their vernacular language ) they will be enrolled in the 
study. 
6. Treatment would be provided free of cost. 
7. In case of any adverse reactions, the patients will be referred to the OPD of 
Kuzhanthai Maruthuvam Department of Govt, Siddha Medical College and 
Hospital, Palayamkottai for further management. 
8. The Patient will be allowed to withdraw from this trail if their parents or 
guardian are not satisfied with this treatment and procedures. 
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5. DRUG REVIEW 
PREPARARTION AND PROPERTIES OF TRIAL DRUG 
Rfe;j ky;yp #uzk; ; ; ;; ; ;; ; ; (cl;gpuNahfk;;; ;); ;; ;; ;; 
NrUk; ruf;Ffs;; ; ;; ; ;; ; ;: 
S.NO NAME BOTANICAL NAME QUANTITY 
1. gwq;fprf;if Smilax china 35 gm 
2. Vyk; Elettaria cardamom 35 gm 
3. mjpkJuk; Glycyrrhiza glabra 35 gm 
4. rd;dytq;fgl;il Cinnamomum verum 35 gm 
5. fUQ;rPufk; Nigella sativa 35 gm 
6. fpuhk;G Syzygium aromaticum 35 gm 
7. tpijapy;yh jpuhl;ir Vitis vinifera 35 gm 
8. rPufk; Cumunim cyminum 35 gm 
9. rh[puh Carum bulbocastanum 35 gm 
10. nfhj;jky;yp tpij Coriandrum sativum 315 gm 
11. fw;fz;L Borossus flabellifer 630 gm 
 
nra;Kiw:;;;  
  ,q;F $wg;gl;l 10 ruf;Ffspy; nfhj;jky;yp tpijia kl;Lk; ed;whf 
utpapy; cyh;j;jpAk; kw;w 9 ruf;Ffis nghd;dpwkhf tWj;J ahitAk; 
,bj;J #uzpj;J rkndil fw;fz;L #uzk; fye;J itj;Jf; nfhs;sTk;. 
msT: 
 ½ fpuhk; (%d;WNtis czTf;F gpd;) 
ehs; msT;;; : 
  14  ehl;fs; 
mDghdk;:;;;  
 ghy; 
Ehy; Mjhuk;;; ;: 
 ek; ehl;L itj;jpak; ghfk;-II gf;f vz;:182 
Ehy; Mrphpah;;; ;: 
 S.tPu ngUkhs; gps;is 
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Fig. 1. INGREDIENTS OF SUGANTHA MALLI CHOORANAM 
 
hxr<gqs<sg<jg< < << < << < < !
!)Smilax china) 
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)Elettaria cardamom) 
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)Cinnamomum verum) 
 
gVR<sQvgl<< Q << Q << Q <!
)Nigella sativa) 
gqvil<H<<< !
)Syzygium aromaticum) 
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INGREDIENTS OF SUGANTHA MALLI CHOORANAM 
 
uqjkbqz<zi!kqvim<js< << << < !
!)Vitis vinifera) 
sQvgl<Q <Q <Q <!
)Cuminum cyminum) 
 
sii<\qvi<<< !
)Carum bulbocastanum) 
ogik<klz<zq!uqjk< << << < !
)Coriandrum sativum) 
 
gx<g{<M< << << < !
)Borossus flabellifer) 
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Fig.2 
SUGANTHA MALLI CHOORANAM 
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PROPERTIES OF TRIAL MEDICINE 
gwq;fprf;if; ;; ;; ;  
 
Botanical Name :   Smilax china 
Family   :    Liliaceae 
Part used  :   Rhizome 
Rit   :  ,dpg;G 
jd;ik  :  jl;gk; 
gphpT   :  ,dpg;G 
nra;if  :  clw;Nww;wp – Alterative  
    Nkfg;gpzptpyf;fp – Antisyphilitic 
    fhkk;ngUf;fp – Aphrodisac 
    Jha;ikahf;fp – Depurative 
Chemical constituents: 
  Kaempferol, Engelatin, Rutin, Vanillic acid, β Sitosterol. 
nghJ Fzk;:;;;  
  jhfk; gythje; jhJel;lk; Gz;gpsit 
 Nkfq; fbfpue;jp tPo;%ye; - NjfKld; 
 Fl;il gfe;jNkw; nfhs;tkdk; Nghk;gwq;fpg; 
 gl;ilapid Ar;rhpj;Jg; ghh; 
       - Fzghlk; %ypif tFg;G 
 
Vyk;;;; 
 
Botanical Name :    Elettaria cardamom 
Family   :    Zingiberaceae 
Part used  :    Seed 
Rit   :  fhh;g;G 
jd;ik  :  ntl;gk; 
gphpT   :  fhh;g;G 
nra;if  :  ntg;gKz;lhf;fp – Stimulant 
    mfl;Ltha;tfw;wp – Carminative 
    grpj;jPj;Jhz;b – Stomachic 
Chemical constituents: 
 Cineole, Terpinyl acetate, Terpineole, Borneole, Terpinene. 
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nghJFzk;:;;;  
 njhz;il tha;fTs; jhYF jq;fspy; 
   Njhd;Wk; Nehajp rhuk;gd; Nkfj;jhy; 
 cz;il Nghy;vOq; fl;b fphpr;ruk; 
   coiy the;jp rpye;jp tprQ;Ruk; 
 gz;il ntf;if tpjhfNeha; fhrKk; 
   ghOQ; Nrhkg; gpzptpe;J el;lKk; 
 mz;il aPistd; gpj;jk; ,itf;nfy;yhk; 
   My khq;fko; Vy kUe;jNj...  
       - Fzghlk; %ypif tFg;G 
 
mjpkJuk;;;; 
 
Botanical Name :    Glycyrrhiza glabra 
Family   :    Fabaceae 
Part used  :    Root 
Rit   :   ,dpg;G 
jd;ik  :   rPjk; 
gphpT   :   ,dpg;G 
nra;if  :   twl;rpafw;wp – Emollient 
cs;soyhw;wp – Demulcent 
Nfhioafw;wp – Mild Epectorent 
kykpsf;fp – Laxative 
cukhf;fp – Tonic 
Chemical constituents: 
  Glycyrrhizine, Glycyrrhetic acid, Liquiritoside, Lichochalcone 
nghJ Fzk;:;;;  
 fj;jpahp Kg;gpzpahy; tUGz; jhfq; 
   fz;Nzha;fs;cd; khjk;tpf;fy; typntz;Fl;lk; 
 gpj;jnkYk; GUf;fp fphpr;ruk; Mth;j;j 
  gpj;jkj %h;r;ir tpl ghfk; ntg;ge; 
jj;jptU thjNrh zpjq;fh khiy 
  rUttplq; fhkpaNeha; jhJ el;lq; 
 Fj;jpUky; Mrpaq;fk; ,jo;Neha; ,e;J 
  Fag;GZk;Nghk; kJhfnkdf; $Wq; fhNy. 
- Njud; Fzthflk; 
  
46 
 
rd;dytq;fgl;il; ; ;; ; ;; ; ;  
 
Botanical Name :    Cinnamomum verum 
Family   :    Lauraceae 
Part used  :    Bark 
Rit   :   fhh;g;G, ,dpg;G 
jd;ik  :   jl;gk; 
gphpT   :   ,dpg;G 
nra;if  :   ntg;gKz;lhf;fp – Stimulant 
mfl;Ltha;tfw;wp – Carminative 
    fhkk;ngUf;fp – Aphrodisiac 
Chemical constituents: 
Cinnamaldehyde, Cinnamate, Cinnamic acid. 
nghJ Fzk;:;;;  
 jhJel;lk; Ngjp rUttp]k; MfpaNeha; 
 G+jfpu fQ;rpye;jpg; G+r;rptplQ; - rhjptplk; 
 Ml;Lkpiug; NghbUky; MfpaNeha;f; $l;lkw 
 Xl;Lkpy tq;fj; Jhp. 
 rd;dytq; fg;gl;il jhd;Fsph;r;rp Az;lhf;Fk; 
 ,d;Dkpuj; jf;fLg;ig aPh;f;Fq;fhz; - Kd;dKWk; 
 ce;jpf fLg;gfw;Wk; cz;%yg; Gz;Nghf;Fk; 
 fe;jkpF G+q;FoNy fhz; 
        - mfj;jpah; Fzthflk; 
 
fUQ;rPufk;; P ;; P ;; P ; 
 
Botanical Name :     Nigella sativa 
Family   :     Ranunculaceae 
Part used  :     Seed 
Rit   :   ifg;G 
jd;ik  :   ntl;gk; 
gphpT   :   fhh;g;G 
nra;if  :   mfl;Ltha;tfw;wp – Carminative 
     rpWePh;g;ngUf;fp – Diuretic 
      UJTz;lhf;fp – Emmenagogue 
      ghw;ngUf;fp – Galactogogue 
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      GOf;nfhy;yp – Anthelmintic 
      grpj;jPj;J}z;b – Stomachic 
     J}f;Fzpg;GOf;nfhy;yp – Parasiticide 
     twl;rpafw;wp – Emollient 
Chemical constituents: 
  Nigellone, Thymoquinone, Thymol, Carvacrol. 
nghJ Fzk;:;;;  
 fUQ;rP ufj;jhd; fug;gndhL Gz;Zk; 
 tUQ;rpuha;g; gPerK khw;Wk; - mUe;jpdhy; 
 fha;r;ry; jiytypAq; fz;typAk; NghKyfpy; 
 tha;r;r kUe;njdNt it. 
       - mfj;jpah; Fzthflk; 
fpuhk;G;;;  
 
Botanical Name :     Syzygium aromaticum 
Family   :     Myrtaceae 
Part used  :     Flower bud 
Rit   :   fhuKk; tpWtpWg;GKs;sJ 
jd;ik  :   ntl;gk; 
gphpT   :   fhh;g;G 
nra;if  :   ,rptfw;wp - Antispasmodic 
    mfl;Ltha;tfw;wp – Carminative 
grpj;jPj;J}z;b – Stomachic 
Chemical constituents: 
  Carvacrol, Thymol, Eugenol, Cinnamaldehyde 
nghJ Fzk;:;;;  
 gpj;j kaf;fk; NgjpnahL the;jpAk;Nghk; 
 Rj;jtpuj;jf; fLg;Ge; Njhd;WNkh – nkj;j 
 ,ytq;fq; nfhz;ltUf; Nfw; RfkhFk; 
 Kykq;Nf fl;Lnkd tho;j;J. 
 
 Rf;fpyel; lq;fh;z #h;tpaq;f yhQ;rde;jhl; 
 Rpf;fy;tplhr; rh;th rpag;gpzpA – kf;fpf;Fl; 
 lq;fg; G+NthL jhpglUe; Njhd;wpypy; 
 tq;fg;G+ NthLiuj;J th. 
        - mfj;jpah; Fzthflk; 
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jpuhl;ir;;;  
 
Botanical Name :     Vitis vinifera 
Family   :     Vitaceae 
Part used  :     Fruit 
Rit   :   ,dpg;G 
jd;ik  :   jl;gk; 
gphpT   :   ,dpg;G 
nra;if  :   cs;soyhw;wp – Demulcent 
    fopr;rYz;lhf;fp - Laxative 
Chemical constituents: 
 Catechin, Epicatechin, Gallocatechin, Procyanidin. 
 
rPufk;P ;P ;P ; 
Botanical Name :     Cuminum cyminum 
Family   :     Apiaceae 
Part used  :     Fruit 
Rit   :   fhh;g;G, ,dpg;G 
jd;ik  :   jl;gk; 
gphpT   :   ,dpg;G 
nra;if  :   mfl;Ltha;tfw;wp – Carminative 
    ntg;gKz;lhf;fp - Stimulant 
grpj;jPj;J}z;b – Stomachic 
Jth;g;gp - Astringent 
Chemical constituents: 
 a-pinene, limonene, 1,8- cineole, linalool, a-terpineole 
nghJ Fzk;:;;;  
 gpj;jnkD ke;jphpiag; gpd;dg; gLj;jpatd; 
 rj;JUit Ae;Jwe;J rhjpj;J – kj;jndDk; 
 uhridA kPntd;W ez;igg; gyg;gLj;jp 
 NghrdF lhhpnrAk; Nghh;. 
                                 - Njud; ntz;gh 
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gpsg;G rPufk; (rhh; P ;; P ;; P ; ;; ;;[puh) 
 
Botanical Name :     Carum bulbocastanum 
Family   :     Apiaceae 
Part used  :     Fruit 
Rit   :   fhh;g;G, ,dpg;G 
jd;ik  :   jl;gk; 
gphpT   :   ,dpg;G 
nra;if  :   mfl;Ltha;tfw;wp – Carminative 
    rpWePh;g;ngUf;fp – Diuretic 
    UJTz;lhf;fp – Emmenagogue 
Chemical constituents: 
 Dillapiole, Germacrene – β, Nothoapiole, β – selinene 
nghJ Fzk;:;;;  
clYf; fofhk; ciwg;gpj;jk; VFk; 
 mlYW thjk; mjkhk; - fbNrh; 
 jsTeiff; Nfhl;LKiyj; ijaNy ehSk; 
 gpsTeWQ; rPufj;ijg; Ngz; 
     - Fzghlk; %ypif tFg;G 
 
 
nfhj;jky;yp; ;; ;; ;  
    
Botanical Name :     Coriandrum sativum 
Family   :     Apiaceae 
Part used  :     Seed 
Rit   :   fhh;g;G 
jd;ik  :   rPj ntg;gk; 
gphpT   :  fhh;g;G 
nra;if  :   grpj;jPj;J}z;b – Stomachic 
     mfl;Ltha;tfw;wp – Carminative 
ntg;gKz;lhf;fp - Stimulant 
     rpWePh;g;ngUf;fp – Diuretic 
Chemical constituents: 
  Linalool, λ-terpinene, a-pinene, camphor, limonene 
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nghJ Fzk;:;;;  
 nfhj;Jky;yp ntg;gk; Fsph;fha;r;ry; gpj;jke;jQ; 
 rh;j;jptpf;fy; jhfnkhL jhJel;lk; - fj;jpnaOk; 
 thj tpfhh;klh; td;fh;j;j gptpuzk; 
 G+jyj;jpy; yhjfw;Wk; Nghw;W 
       - mfj;jpah; Fzthflk; 
 
fw;fz;L; ;; ;; ;  
Botanical Name :     Borossus flabellifer 
Family   :     Arecaceae 
Part used  :     palm jaggery 
Rit    :   ,dpg;G 
jd;ik   :   jl;gk; 
gphpT    :   ,dpg;G 
 
nghJ Fzk;:;;;  
 Nkf tdYkpf tPRk#hpifahy; 
 Mf KWfdY khWq;fhz; - Nkfdj;jpy; 
 jq;fptU ePh;r;RUf;Fe; jhfntg;g Ke;jzpAk; 
 ,q;Fgdq; fw;fz;Lf; Nf 
         - mfj;jpah; Fzthflk; 
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6. BIO-CHEMICAL ANALYSIS OF SUGANTHA MALLI 
CHOORANAM 
Preparation of the extract:  
 5gms of the drug was weighed accurately and placed in a 250ml clean beaker 
then 50ml of distilled water is added and dissolved well. Then it is boiled well for 
about 10 minutes. It is cooled and filtered in a 100ml volumetric flask and then it is 
making up to 100ml with distilled water.  This fluid is taken for analysis. 
 
QUALITATIVE ANALYSIS 
S.NO EXPERIMENT OBSERVATION INFERENCE 
1.  TEST FOR CALCIUM 
2ml of the above prepared extract is taken 
in a clean test tube. To this add 2ml of 4% 
Ammonium oxalate solution 
A white precipitate is 
formed 
Indicates the 
Presence of 
Calcium 
2. TEST FOR SULPHATE 
2ml of the extract is added to 5% Barium 
chloride solution. 
A white precipitate is 
formed 
Indicates the 
Presence  of 
Sulphate 
3.  TEST FOR CHLORIDE 
The extract is treated with silver nitrate 
solution 
A white precipitate is 
formed 
Indicates the 
presence of  
Chloride 
4. TEST FOR CARBONATE 
The substance is treated with 
concentrated Hcl. 
No brisk 
effervescence is 
formed 
Absence of 
Carbonate 
5. TEST FOR STARCH 
The extract is added with weak iodine 
solution 
Blue colour is 
formed 
Indicates the 
presence of 
Starch 
6.  TEST FOR FERRIC IRON 
The extract is acidified with Glacial 
acetic acid and potassium ferro cyanide. 
No blue colour is 
formed 
Absence of ferric 
Iron 
7. TEST FOR FERROUS IRON  
The extract is treated with concentrated 
Nitric acid and Ammonium thiocyanate 
solution 
Blood red colour is 
formed 
Indicates the 
presence of 
Ferrous Iron 
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8.  TEST FOR PHOSPHATE 
The extract is treated with Ammonium 
Molybdate and concentrated nitric acid 
No yellow 
precipitate is formed 
Absence of 
Phosphate 
9.  TEST FOR ALBUMIN 
The extract is treated with Esbach’s 
reagent 
No yellow 
precipitate is formed 
Absence of 
Albumin 
10.  TEST FOR TANNIC ACID 
The extract is treated with ferric chloride. 
No Blue black 
precipitate is formed 
Absence of 
Tannic acid 
11.  TEST FOR UNSATURATION 
Potassium permanganate solution is 
added to the extract 
It does not gets 
decolourised 
Absence of  
Unsaturated 
compound 
12.  TEST FOR THE REDUCING SUGAR 
5ml of Benedict’s qualitative solution is 
taken in a test tube and allowed to boil for 
2 minutes and add 8-10 drops of the 
extract and again boil it for 2 minutes. 
Colour change 
occurs 
Indicates the 
presene of  
Reducing sugar 
13.  TEST FOR AMINO ACID 
One or two drops of the extract is placed 
on a filter paper and dried well. After 
drying, 1% Ninhydrin is sprayed over the 
same and dried it well. 
Violet colour is 
formed 
Indicates the 
Presence of  
Amino acid 
14. TEST FOR ZINC 
The extract is treated with Potassium 
Ferrocyanide. 
No white precipitate 
is formed 
Absence of Zinc 
 
Inference: 
 The given sample of “SUGANTHA MALLI CHOORANAM” contains 
Calcium, Sulphate, Chloride, Starch, Ferrous Iron, Reducing sugar and Amino acid.
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7. PHARMACOLOGICAL ANALYSIS 
EVALUATION OF ANALGESIC ACTIVITY OF SUGANTHA MALLI 
CHOORANAM 
Analgesic activity: 
   Hot plate method 
Animals  
Young wistar albino rats of either sex aged 4-5 weeks, average weight 100-
150 gm were used for the experiment. The rat were purchased from the animal 
TANVASU. They were kept in standard environmental condition (at 24.0±0°C 
temperature & 55-65% relative humidity and 12 hour light/12 hour dark cycle) for 
one week for acclimation after their purchase and fed ICDDRB formulated rodent 
food and water ad libitum. The set of rules followed for animal experiment were 
approved by the institutional animal ethical committee (Zimmermann, 1983). 
Experimental animals of either sex were randomly selected and divided into 
four groups designated as group-I, group-II, group-III and group-IV consisting of five 
Rats in each group for control, positive control and test sample group respectively. 
Each group received a particular treatment i.e. control (1% Tween-80 solution in 
water, 10ml/kg, p.o.), positive control (Diclofenac sodium 10 mg/kg, p.o.) and the test 
sample (drug of 100 mg/kg, p.o. & 200 mg/kg, p.o. respectively). The animals were 
positioned on Eddy’s hot plate kept at a temperature of 55±0.5 0C. A cut off period of 
15 s (Franzotti et al., 2000) was observed to avoid damage to the paw. Reaction time 
was recorded when animals licked their fore or hind paws, or jumped prior to and 0, 
30, 60 and 90 min after oral administration of the samples (Eddy et al., 1953; 
Kulkarni, 1999; Toma et al., 2003). 
Statistical analysis  
The results of statistical analysis for animal experiment were expressed as 
mean ± SEM and were evaluated by ANOVA followed by Dunnet’s multiple 
comparisons. The results obtained were compared with the vehicle control group. The 
p<0.05, 0.001 were considered to be statistically significant. 
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GROUP DOSE 
Mean latency before and after drug 
administration % inhibition 
0 min 30 min 60  min  90 min 30min 60min 90min 
Group  
I Vehicle 2.96±0.220 3.35±0.226 2.86±0.198 3.28±0.267 - - - 
Group  
II 10 3.04±0.088 6.32±0.625 8.67±0.645 12.37±1.008 46.99 67.01 73.48 
GROUP 
III 100 2.91±0.074 3.97±0.265 5.89±0.776 5.87±0.617 15.61 51.44 44.12 
Group 
IV 200 2.77±0.018 4.27±0.852 7.04±0.514 6.63±0.465 21.54 59.37 50.52 
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Result:  
Results of hotplate test are presented in Table for drugs respectively. The drug 
Sugantha Malli Chooranam  were found to exhibit a dose dependent increase in 
latency time when compared with control. At 90 minutes, the percent inhibition of 
two different doses (100 and 200 mg/kg body weight) was 50.09% & 56.49% 
respectively. The results were found to be statistically significant (p<0.001)  
Discussion: 
Siddha is the foremost system of medicine to emphasize health as the perfect 
state of physical, psychological, social and spiritual components of a human being. 
The fundamental principle of this medicine successfully eliminates the evil side 
effects without losing the beneficial medicinal properties. Diclofenac was used as a 
reference drug in the current study as it has both central, peripheral actions and can 
significantly treat nociceptive pain as in this model. [11] In the current study, pain 
threshold increased significantly during the period of observation in all the drug 
treated groups, with maximum effect observed in the Sugantha Malli Chooranam at a 
dose of 200mg/kg as shown in table 1. The analgesic activity of Sugantha Malli 
Chooranam was comparable to diclofenac at 30, 60,120 minutes appears to be a 
significant finding and suggests that this drug has a slow onset of analgesic action. 
Conclusion: 
Sugantha Malli Chooranam  possess significant analgesic action in the  
preclinical study. These findings support the use of Sugantha Malli Chooranam   in 
traditional system of medicine for the management of pain. Further studies are needed 
to be carried out in other animal models - pain to validate its efficacy and to identify 
the active phyto-constituents in the formulation and their targets in pain  pathways. 
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ANTI-INFLAMMATORY ACTIVITY OF SUGANTHA MALLI CHOORANAM 
 
The anti-inflammatory activity of Sugantha Malli Chooranam at 100 and 200 
mg/kg doses were evaluated using carrageenan-induced paw edema method. The 
inflammation was readily produced in the form of edema with the help of irritant such 
as carrageenan. Carrageenan is a sulphated polysaccharide obtained from sea weed 
(Rhodophyceae), when it injected it  release the prostaglandins by the way it produces 
inflammation and edema. 
 
REQUIREMENTS: 
Animal                         :  Albino rat (180-200 g) 
Drugs and chemicals           :  Carrageenan (1%w/v),  
            Diclofenac sodium (standard), 
            Carboxy methyl cellulose (1%w/v), 
                 Plethysmo meter. 
Test compounds                :     Sugantha Malli Chooranam. 
 
METHOD: 
  Anti-inflammatory activity was performed by the following procedure of 
Bhandri et al(1) The animals were divided into 4 groups each having six animals. A 
freshly prepared suspension of carrageenan (1% w/v , 0.1 ml) was injected to the 
planter region of left hind paw of each rat. One group was kept as control and the 
animals of the other groups were pretreated with the Sugantha Malli Chooranam test 
Compounds dissolved with 2 ml sterile water given through orally 30 min before the 
carrageenan treatment. The paw volumes of the test compounds, standard and control 
groups were measured at 60, 240, 360 minutes of carrageenan treatment with the help 
of  plethysmometer. Mean increase in paw volume was measured and the percentage 
of inhibition was calculated. 
% Anti-inflammatory activity = (Vc-Vt / Vc) x 100 
  Where, Vt-mean increase in paw volume in rats treated with test compounds, 
  Vc-mean increase in paw volume in control group of rats. 
 
  
57 
 
TABLE NO.1 
ANTI-INFLAMMATORY ACTIVITY OF SUGANTHA MALLI CHOORANAM 
Treatment Dose (mg/kg) 
Paw volume(ml) 
as measured by 
mercury 
displacement at 6 
hour 
Percentage 
inhibition of paw 
edema 
Group I 
Normal saline 
10ml/kg orally 5.90±0.96 - 
Group II 
Std 
10mg/kg 
I.P.Diclofenac 
sodium 
2.40±0.40 59.32%*a 
Group III 
Sugantha Malli 
Chooranam 
100mg/kg.Orally. 2.76±0.48 53. 22%*a 
Group IV 
Sugantha Malli 
Chooranam 
200mg/kg.Orally. 2.60±0.52 55.93%*a 
* Data are expressed as Mean ± S.E.M. 
*Data were analyzed by one way ANOVA followed by Newman’s keul’s multiple 
range tests, to determine the significance of the difference between the control group 
and rats treated with the test compounds. 
*a   Values were significantly different from normal control at P< 0.01. 
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Results 
  Sugantha Malli Chooranam at 100 and 200 mg/kg doeses were tested for their 
Anti- inflammatory activity by using carrageenan Induced rat paw edema method and 
the results are tabulated in table no 1.  The results reveals that   both extracts of 
Sugantha Malli Chooranam at 100 and 200 mg/kg doses possesses significant Anti- 
inflammatory activity when compared to control group at p<0.01. 
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TOXICITY STUDIES 
EVALUATION OF ACUTE TOXICITY STUDY OF SUGANTHA MALLI 
CHOORANAM 
Effect of Acute Toxicity Study (14 Days) of SUGANTHA MALLI 
CHOORANAM 
Table no –1   Physical and behavioral examinations. 
Group 
no. 
Dose(mg/kg) Observation 
sign 
No. of animal affected. 
Group-I 5mg/kg Normal 0 of 3 
Group- II 50mg/kg Normal 0 of 3 
Group-III 300mg/kg Normal 0 of 3 
Group-IV 1000mg/kg Normal 0 of 3 
Group-V 2000mg/kg Normal 0 of 3 
 
Table no-2    Home cage activity 
 
  
Functional 
and 
Behavioural 
observation 
Observation 
5mg/kg 
Group 
(G-I) 
50mg/kg 
(G-II) 
300mg/kg 
(G-III) 
 
1000mg/kg 
(G-IV) 
2000mg/kg 
(G-V) 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Body 
position Normal 3 3 3 3 3 
Respiration Normal 3 3 3 3 3 
Clonic 
involuntary 
Movement 
Normal 3 3 3 3 3 
Tonic 
involuntary 
Movement 
Normal 3 3 3 3 3 
Palpebral 
closure Normal 3 3 3 3 3 
Approach 
response Normal 3 3 3 3 3 
Touch 
response Normal 3 3 3 3 3 
Pinna reflex Normal 3 3 3 3 3 
Tail pinch 
response Normal 3 3 3 3 3 
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Table no-3  Hand  held  observation 
Functional 
and 
Behavioral 
observation 
Observation 
Contr
ol 
5 mg/ 
kg 
(G-I) 
50 
mg/kg 
(G-II) 
300mg/
kg 
(G-III) 
1000mg/
kg 
(G-IV) 
2000mg/
kg 
(G-V) 
Femal
e n=3 
Femal
e n=3 
Femal
e n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Reactivity Normal 3 3 3 3 3 3 
Handling Normal 3 3 3 3 3 3 
Palpebral 
closure 
Normal 3 3 3 3 3 3 
Lacrimation Normal 3 3 3 3 3 3 
Salivation Normal 3 3 3 3 3 3 
Piloerection Normal 3 3 3 3 3 3 
Pupillary 
reflex 
Normal 3 3 3 3 3 3 
Abdominal 
tone 
Normal 3 3 3 3 3 3 
Limb tone Normal 3 3 3 3 3 3 
 
Table no-4 Mortality 
Group no Dose no(mg/kg) Mortality 
Group-I 5(mg/kg) 0 of 3 
Group-II 50(mg/kg) 0 of 3 
Group-III 300(mg/kg) 0 of 3 
Group-IV 1000(mg/kg) 0 of 3 
Group-V 2000(mg/kg) 0 of 3 
 
RESULT: 
  From acute toxicity study it was observed that the administration of 
SUGANTHA MALLI CHOORANAM at a dose of 2000 mg/kg to the rats do not 
produce drug-related toxicity and mortality. So No-Observed-Adverse-Effect- 
Level (NOAEL) of SUGANTHA MALLI CHOORANAM  is 2000 mg/kg. 
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DISCUSSION 
  SUGANTHA MALLI CHOORANAM was administered single time at the 
dose of 5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats and 
observed for consecutive 14 days after administration. Doses were selected based 
on the pilot study and literature review. All animals were observed daily once for 
any abnormal clinical signs. Weekly body weight and food consumption were 
recorded. No mortality was observed during the entire period of the study. Data 
obtained in this study indicated no significance physical and behavioural signs of 
any toxicity due to administration of SUGANTHA MALLI CHOORANAM at the 
doses of 5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats.  
  At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand 
held activity were observed. Home cage activities like Body position, Respiration, 
Clonic involuntary movement, Tonic involuntary movement, Palpebral closure, 
Approach response, Touch response, Pinna reflex, Sound responses, Tail pinch 
response were observed. Handheld activities like Reactivity, Handling, Palpebral 
closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominaltone, 
Limb tone were observed. Functional and behavioral examination was normal in all 
treated groups.Food consumption of all treated animals was found normal as 
compared to normalgroup. 
  Body weight at weekly interval was measured to find out the effect of 
SUGANTHA MALLI CHOORANAM on the growth rate. Body weight change in 
drug treated animals was found normal. 
 
INTERPRETATION: 
 SUGANTHA MALLI CHOORANAM was administered single time at the 
dose of 5mg/kg, 50mg/kg, 300mg/kg, 1000mg/kg and 2000mg/kg to rats and 
observed for consecutive 14 days after administration. Doses were selected based 
on the pilot study and literature review. All animals were observed daily once for 
any abnormal clinical signs. Weekly body weight and food consumption were 
recorded. No mortality was observed during the entire period of the study. Data 
obtained in this study indicated no significance physical and behavioural signs of 
any toxicity due to administration of SUGANTHA MALLI CHOORANAM at the 
doses of 5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats.  
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At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand 
held activity were observed. Home cage activities like Body position, Respiration, 
Clonic involuntary movement, Tonic involuntary movement, Palpebral closure, 
Approach response, Touch response, Pinna reflex, Sound responses, Tail pinch 
response were observed. Handheld activities like Reactivity, Handling, Palpebral 
closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominaltone, 
Limb tone were observed. Functional and behavioral examination was normal in all 
treated groups. Food consumption of all treated animals was found normal as 
compared to normal group. 
  Body weight at weekly interval was measured to find out the effect of 
SUGANTHA MALLI CHOORANAM on the growth rate. Body weight change in 
drug treated animals was found normal. 
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SUB-ACUTE TOXICITY STUDY IN WISTAR RATS TO EVALUATE 
TOXICITY PROFILE OF SUGANTHA MALLI CHOORANAM 
 
Table : 5 EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF SUGANTHA 
MALLI CHOORANAM ON BODY WEIGHT IN GRAM 
 
GROUP CONTROL LOW MID HIGH 
1st day 122.5±3.06 115±7.876 124.3±5.231 126.3±5.23 
7th day 123.3±3.06 122.3±7.676 123±5.113 128±5.11 
14th day 125.1±3.007 93.3±7.45 94.4±5.012 94.4±5.012 
21st day 94.3±5.450 101.2±7.804 102±4.131 96±4.13 
28th day 104.3±3.074 103.3±4.202 134±5.0405 137±5.040 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by Dennett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group. 
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EFFECT OF SUBACUTE DOSE (28 DAYS) OF SUGANTHA MALLI 
CHOORANAM 
Table : 6 SUGANTHA MALLI CHOORANAM ON ORGAN WEIGHT 
(PHYSICAL PARAMETER) IN GRAM 
GROUP CONTROL LOW MID HIGH 
HEART 2.39±0.02 2.40±0.04 2.43±0.11 2.44 ±0.02 
LIVER 8.27± 0.23 8.29±0.23 8.16±0.01 8.18± 0.23 
LUNGS 4.27±0.10 4.27±0.14 4.30±0.24 4.33±0.10 
KIDNEY L 1.39±0.02 1.39±0.03 1.40±0.02 1.41±0.02 
 R 1.37±0.024 1.40±0.02 1.41±0.024 1.42±0.024 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF SUGANTHA MALLI 
CHOORANAMON HAEMATOLOGICAL PARAMETERS 
Table no : 7 
Drug 
treatm
ent 
RBC 
million 
cells/c
mm 
WBC  
cells/cmm 
Haemoglob
ingm % 
Differential count % 
Neutrop
hils 
Eosinop
hils 
Monoc
yte 
Lympho
cyte 
Contr
ol 
7.22±0.
60 
5253.40±2
5.34 
15.39±2.47 32.26±1.
20 
2.51±2.1
1 
0.64±2.
15 
24.12±5.
32 
LOW  5.48±0.
40 
4335.03±2
5.24 
15.19±2.45 26.53±1.
43 
3.09±2.1
4 
0.31±2.
30 
24.21±5.
51 
MID 5.34±0.
23 
4305.24±3
3.37 
15.09±3.05 31.31±2.
22 
2.43±2.1
2 
0.61±2.
40 
24.12±5.
32 
HIGH 6.27±0.
23 
5189.24±3
4.37 
17.10±3.07 29.31±2.
22 
2.49±2.1
2 
0.63±2.
40 
25.12±5.
32 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by Dennett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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Table : 8  EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF SUGANTHA 
MALLI CHOORANAM ON BIOCHEMICAL PARAMETER 
        
Drug 
Treatment 
SGPT 
(IU/L) 
SGOT 
(IU/L) 
ALP 
(IU/L) 
Urea 
(mg/dl) 
Creatinine 
(mg/dl) 
Control 41.13±3.02 14.23±4.31 242.10±11.32 34.34±3.00 0.53±0.03 
LOW 41.12±3.22 14.22±4.01 250.10±12.42 39.52±2.42 0.39±0.04 
MID 39.20±4.44 14.30±2.21 244.44±4.14 38.11±2.22 0.44±0.04 
HIGH 41.20±4.44 13.30±2.21 233.44±4.14 39.11±2.22 0.65±0.04 
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EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF SUGANTHA MALLI 
CHOORANAM BIOCHEMICAL PARAMETERS 
Table: 9 
GROUP CONTROL SMC 
(200mg/kg) 
SMC 
(400mg/kg) 
SMC 
(600mg/kg) 
TOTAL 
BILIRUBIN 
(mg/dl) 
0.8±0.2457 1.4±0.27 0.88±0.76 0.14±0.199 
  
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dennett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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EFFECT OF SUB - ACUTE DOSE (28 DAYS) OF SUGANTHA MALLI 
CHOORANAM ON BIOCHEMICAL PARAMETERS 
Table: 10 
GROUP CONTROL SMC (200mg/kg) 
SMC 
(400mg/kg) 
SMC 
(600mg/kg) 
CREATININE 
(mg/dl) 
0.533±0.03849 
 
0.533±0.088
27 0.720.0446 
0.572±0.0252
8 
 
URIC ACID 
 (mg/dl) 
 
1.552±0.2766 
 
1.579±0.160 
 
2.046±0.661
7 
 
1.588±0.2929 
 
. 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF SUGANTHA MALLI 
CHOORANAM ON FOOD INTAKE IN GRAM 
Table: 11 
GROUP CONTROL Low mid high 
1st DAY 19.34±13.5110 20.1673±14.3 12.12±21.71 18.6±7.62 
7th DAY 15.6±11. 11.864±12.67 16.75±9.853 12.18±14.41 
14th DAY 19.84±8.72 11.84±14.28 11±13.96 20.73±8.981 
21st DAY 12.86±12.4 16±8.466 16.88±9.43 20.18±8.02 
28th DAY 13.11±11.38 19.39±11.50 11±8.90 11±7.57 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group 
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EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF  SUGANTHA MALLI 
CHOORANAM ON WATER INTAKE IN ML 
Table: 12 
GROUP CONTROL 
SMC 
(200mg/kg) 
SMC 
(400mg/kg) 
SMC 
(600mg/kg) 
1st DAY 98.38±13.10 89.72±14.3426 102.10±21.199 67.5±7.03 
7th DAY 85.5±11.78 100.863±12.70 76.63±9.363 81.17±14.50 
14th 
DAY 
58.33±8.817 90.8363±14.12 80±13.92 89.12±8.81 
21st DAY 91.67±12.49 85±8.462 65.838±9.450 89.17±8.702 
28th 
DAY 
82.10±11.30 88.48±11.504 80±8.061 70±7.53 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group 
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EFFECT OF SUB ACUTE DOSES (28 DAY) OF SUGANTHA MALLI 
CHOORANAM ON ELECTROLYTES 
Table: 13 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dennett’s(n=6); NS- non-significant, *p<0.05, 
**p<0.01, ***p<0.001,  
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RESULTS: 
CLINICAL SIGNS: 
  All animals in this study were free of toxic clinical signs throughout the 
dosing   period of 28 days. 
Mortality: 
  All animals in control and in all the treated dose groups survived 
throughout the dosing period of 28 days. 
 Body weight: 
  Results of body weight determination of animals from control and different 
dose groups exhibited comparable body weight gain throughout the dosing period 
of 28 days. 
Food consumption: 
  During dosing and the post-dosing recovery period, the quantity of food 
consumed by animals from different dose groups was found to be comparable with 
that by control animals. 
Organ Weight: 
  Group Mean Relative Organ Weights (% of body weight) are recorded in 
Table No.22 Comparison of organ weights of treated animals with respective 
control animals on day 29 was found to be comparable similarly. 
Hematological investigations: 
  The results of hematological investigations conducted on day 29 revealed 
following significant changes in the values of different parameters investigated 
when compared with those of respective controls; however, the increase or 
decrease in the values obtained was within normal biological and laboratory limits 
or the effect was not dose dependent. 
Biochemical Investigations: 
  Results of Biochemical investigations conducted on the day 29th and 
recorded in Table no 24, 25 revealed the following significant changes in the values 
of hepatic serum enzymes studied. When compared with those of respective 
control. However, the increase or decrease in the values obtained was within 
normal biological and laboratory limits. 
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INTERPRETATION: 
1. All the animals from control and all the treated dose groups up to 
2000mg/kg survived throughout the dosing period of 28 days. 
2. No signs of toxicity were observed in animals from different dose groups 
during the dosing period of 28 days. 
3. Animals from all the treated dose groups exhibited comparable body weight 
gain with that of controls throughout the dosing period of 28 days. 
4. Food consumption of control and treated animals was found to be 
comparable throughout the dosing period of 28 days 
5. Haematological analysis conducted at the end of the dosing period on day 
29th, revealed no abnormalities attributable to the treatment. 
6. Biochemical analysis conducted at the end of the dosing period on day 29th, 
no abnormalities attributable to the treatment. 
7. Organ weight data of animals sacrificed at the end of the dosing period was 
found to be comparable with that of respective controls. 
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8. ANTIMICROBIAL STUDY REPORT 
AIM 
To study the Anti-microbial action of Sugantha Malli Chooranam 
against Streptococcus pneumoniae, Staphylococcus aureus and other bacterias 
such as Pseudomonas aeruginosa, Escherichia coli 
 
MEDIUM 
Muller Hinton agar 
 
COMPONENTS OF MEDIUM 
Beef extract   - 300gms/lit 
Agar   - 17gms/lit 
Starch   - 1.5gms/lit 
Casein Hydroxylate - 17.5gms/lit 
Distilled water - 1000ml 
PH   - 7.6 
 
PROCEDURE 
The media was prepared from the components and poured and dried on a 
petri dish. The organism was streaked on the medium and the test drug (1gm drug 
in 10ml water) was placed on the medium. This is incubated at 370C for one over 
night and observed for night and observed for the susceptibility shown up 
clearance around the drug. 
 
RESULT: 
The test drug Sugantha Malli Chooranam was resistant against 
Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, 
Escherichia coli. 
S.NO ORGANISM SENSITIVITY ZONE OF DRUG 
ZONE OF 
CONTROL 
1 Streptococcus 
pneumoniae 
Resistant - 16mm 
(amikacin) 
2 Staphylococcus 
aureus 
Resistant - 18mm 
(erythromycin) 
3 Pseudomonas 
aeruginosa 
Resistant - 16mm 
(erythromycin) 
4 Escherichia coli Resistant - 15mm 
(erythromycin) 
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Fig. 3 
REPRESENTATIVE PICTURE OF THE  
ANTIMICROBIAL STUDY 
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9. OBSERVATION AND RESULTS 
1.AGE DISTRIBUTION: (Table No:1) 
S.NO Age No. Of Cases (out of 40) 
 
Percentage 
(%) 
 
1 0-1 Year 
Kappu and Chenkeerai 
-  
2 2 years-3 years 
Varugai,Thalattu,Sappani,Mutham 
-  
3 4  years-6 years 
Ambuli,Chitril,Chiruparai,Chiruthervidal,Paethai(fem
ale)and Pillai(male)paruvam 
09 22.5% 
4 7 years-10years 
Paethamai(female) 
Chiruparuvam(male) 
22 55% 
5 11years-12 years 
Mangai(female),Valibam(male) 
09 22.5% 
 
 
 
Children under the age group of 7 years to 10 years were commonly affected. 
Among school going children, chocolates consuming  children had high incidence of 
tonsillar infection. 
 
 
22.50%
55%
22.50%
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2. SEX-DISTRIBUTION: (Table No:2) 
 
S.No Sex 
No.of cases 
(out of 40) 
Percentage(%) 
1 Male children 16 40% 
2 Female children 24 60% 
     
 
 
 
  Among 40 cases studied 16 were male children (40%) and 24 were female 
children (60%).Female children were highly affected than male children. 
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3. SOCIO-ECONOMIC STATUS: (Table No:3) 
 
S.No Socio-economic status 
No.of cases 
(out of 40) Percentage(%) 
1 Poor 10 25% 
2 Middle Class 30 75% 
3 Rich - - 
    
 
 
 
 
  According to this study, the disease Lasunathabitham was noticed in 10 cases 
(25%) belonging to poor socio economic status,due to lack of nutritious food and and 
30 cases (75%) noticed in  Middle class due to unhygienic condition . 
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4.DISTRIBUTION OF PARUVA KALANGAL (Table No:4) 
 
S.No Paruvakaalam 
No.of cases 
(out of 40) 
Percentage(%) 
1 Kaar(Aavani,Purattasi) 14 35% 
2 Koothir(Ayppasi,Karthigai) 02 05% 
3 Munpani(Markazhi,Thai) 02 05% 
4 Pinpani(Maasi,Pankuni) 07 17.5% 
5 Ela Venil(Chithirai,Vaikasi) 05 12.5% 
6 Muthuvenil(Aani,Aadi) 10 25% 
    
 
 
 
  The incidence of cases in Kaar kaalam 35%, Koothir kaalam 5%, Munpani 
kaalam 5%, Pinpani kaalam 17.50%, Elavenir kaalam 12.50% and Muthuvenir 
kaalam 25% of cases were affected by Lasunathabitham was  noted. 
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5. DIET HISTORY (Table No:5) 
 
S.No Type of Diet 
No.of cases 
(out of 40) 
Percentage(%) 
1 Vegetarian 08 20% 
2 Mixed 32 80% 
 
 
 
 
 
  According to diet history, high incidence of cases 80% was noted in mixed 
diet and 20% of cases are noted in vegetarian diet. 
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6.FAMILY HISTORY (Table No:6) 
 
S.No FAMILY HISTORY 
No.of cases 
(out of 40) 
Percentage(%) 
1 Positive Family History 4 10% 
2 Negative Family History 36 90% 
 
 
 
 
 
 
  Out of 40 cases 36 (90%) cases had negative family history and 4 (10%) cases 
had positive family history. 
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7.DISTRIBUTION OF LANDS (Table No:7) 
 
S.No Distribution of Lands 
No.of cases 
(out of 40) Percentage(%) 
1 Kurinji (Hill) - - 
2 Mullai (Forest) - - 
3 Marutham (Fertile) 32 80% 
4 Neithal (Coastal) 08 20% 
5 Paalai (Desert) - - 
 
 
 
 
  The incidence of Lasunathaitham among the people residing in the Marutham 
Nilam was more, due to altered life style and changed environmental conditions. 
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8. MUKKUTRA THEORY (Table No:8) 
 
I.DEARANGEMENT OF VATHAM 
 
S.No Types of Vatham 
No.of cases 
(out of 40) 
Percentage(%) 
1 Pranan 40 100 
2 Abanan 12 30 
3 Viyanan 40 100 
4 Uthanan 40 100 
5 Samanan 40 100 
6 Naagan - - 
7 Koorman - - 
8 Kirukaran 40 100 
9 Devathathan 40 100 
10 Dhananjeyan - - 
 
  In Vatham, all cases had dearangement in Pranan, Viyanan, Uthanan, 
Samanan, Kirugaran, Devathathan. In 30% of cases Abanan was affected. 
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II.DEARANGEMENT OF PITHAM 
 
S.No Types of Pitham 
No.of cases 
(out of 40) Percentage(%) 
1 Anilapitham 12 30 
2 Ranjakapitham 12 30 
3 Saathakapitham 40 100 
4 Pirasakapitham - - 
5 Aalosakapitham - - 
 
 
 
 
 
  In Pitham, incidence of Analpitham and Ranjakapitham affected in 30% of 
cases. In Sathakapitham 100% of patients were affected. 
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III.DEARANGEMENT OF KABAM 
 
S.No Types of Kabam 
No.of cases 
(out of 40) 
Percentage(%) 
1 Avalambakam 40 100 
2 Kilethakam - - 
3 Pothakam -                 - 
4 Tharpakam - - 
5 Santhikam - - 
 
 
 
 
  In Kapham, the incidence of Avalambakam affected in all 40 cases was 100%. 
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9. UDAL KATTUGAL (Table No:9) 
 
S.No UDAL KATTUGAL 
No.of cases 
(out of 40) Percentage(%) 
1 Saaram 40 100 
2 Senneer 12 30 
3 Oon 40 100 
4 Kozhuppu - - 
5 Enbu - - 
6 Moolai - - 
7 Sukkilam/Suronitham - - 
 
 
 
 
  In Udal kattugal, Saaram and Oon was affected in all patient because of 
increased Kabam. Incidence of Senneer affected in patients were 30%. 
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10.ENN VAGAI THERVUGAL  (Table No:10) 
S.No 
ENN VAGAI 
THERVUGAL 
No.of cases(out of 
40) Percentage (%) 
1 Naadi 
A. Vathapitham 
B. Pithakabam 
C. Vathakabam 
D. Kabapitham 
E. Pithavatham 
F. Kabavatham 
 
02 
18 
  - 
14 
04 
02 
 
5 
45 
  - 
35 
10 
5 
 
2 Sparisam 10 25 
3 Naa 12 30 
4 Niram 40 100 
5 Mozhi 40 100 
6 Vizhi 12 30 
7 Malam 12 30 
8 Moorthiram   -   - 
 
 
 
  In Envagai thervugal, pale appearance and white coating of tongue, dull voice, 
redness of eyes, fever and burning micturition were noticed respectively. 
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11.NEI KURI (Table No:11) 
S.No Neikuri Reference Character of Urine 
No.of cases 
(out of 40) 
Percentage 
(%) 
1 Vatha Neer Spreads like Snake 4 10 
2 Pitha Neer Spreads like Ring 15 37.5 
3 Kaba Neer Spreads like Pearl 21 52.5 
 
 
 
  Among the 40 cases, 10% cases were observed Vatha Neer, 38% case Pitha 
Neer and 53% cases were Kabha Neer. 
 
 
 
 
 
 
 
 
 
 
 
  
Vatha neer
10%
Pitha neer
38%
kapa neer
52%
NEI KURI
94 
 
12. ETIOLOGICAL FACTORS OF LASUNATHABITHAM (Table No:12) 
 
 
 
 
  From the study, the author concludes that the main cause for the occurrence of 
Lasunathabitham was intake of cold food stuffs like ice creams and drinking of 
contaminated water. Seasonal variations,living in congested area,Family history are 
the other causes of Lasunathabitham. 
 
 
 
 
 
 
87.50%
50%
75%
25%
Intake of cold food 
stuffs, cool drinks, ice 
creams
Drinking 
contaminated water
Seasonal variations Living styles
AETIOLOGICAL FACTOR
S.No Etiological factors 
No.of cases 
(out of 40) 
Percentage 
(%) 
1 Intake of cold food stuffs,cool 
drinks,Ice creams 
35 87.5 
2 Drinking contaminated water 20 50 
3 Seasonal Variations 30 75 
4 Family History - - 
5 Living in congested 
areas,using same vessels by 
many 
10 25 
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13. CLINICAL FEATURES-SIGNS AND SYMPTOMS (Table No:13) 
The signs and symptoms of patients with Lasunathabitham under the clinical 
study was given below 
S.No Clinical Features 
No.of cases 
(out of 40) 
Percentage 
(%) 
1 Sore throat 40 100 
2 Dysphagia 35 87.5 
3 Redness and swelling of the tonsil 40 100 
4 Nasal congestion and Nasal discharge 14 35 
5 Cough 35 87.5 
6 Hoarseness of voice 35 87.5 
7 Headache 5 12.5 
8 Cervical lymphadenitis 30 75 
9 Fever 20 50 
10 Nausea 2 5 
11 Ear ache 20 50 
12 Halitosis 10 25 
13 Constipation 15 37.5 
14 Distaste - - 
     
 
  Most of the patients had high incidence of sore throat, cough, redness and 
swelling of tonsils, dysphagia, cervical lymphadenitis were noted. 
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 14. RESULTS AFTER TREATMENT
 
S.No Result
1 
2 Moderate
3 
         
 
  10 cases (25%) showed moderate results, 30 cases (75%) showed good results. 
These results were based on the clinical improvement.
 
good
75%
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 (TOTAL) (Table No:14)
 No.of cases 
(out of 40) 
Mild - 
 10 
Good 30 
 
 
 
Moderate
25%
 
Percentage 
(%) 
- 
25 
75 
 
 Patient Name:    Girl. Mahalakshmi        Age: 5 Yrs         Sex: Female Child
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Fig. 4 
 
BEFORE TREATMENT 
 
TREATMENT AFTER  5 DAYS 
 
AFTER TREATMENT- 14 DAYS 
 
 
 Patient name:  Master Mathan           Age:   11 Yrs             Sex: Male Child
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Fig  5 
 
 
 
BEFORE TREATMENT 
 
 
 
 
TREATMENT AFTER 5 DAYS 
 
 
AFTER TREATMENT – 14 DAYS 
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HEMATOLOGICAL INVESTIGATIONS : 20 INPATIENTS OF LASUNATHABITHAM 
 
 
S.NO 
 
IP NO 
 
Name of the patient 
HEMATOLOGICAL INVESTIGATIONS 
Before   Treatment After Treatment 
TCL 
Cu mm 
DC% ESR mm HB 
gms
% 
TCL 
Cu 
mm 
DC% ESR mm HB 
gms% 
P L E ½ hr 1 hr  P L E ½ hr 1 hr  
1 1409 L.VISHNU 7600 66 31 3 8 15 12.6 7600 66 32 2 5 10 12.6 
2 1410 L.ELAKKIYA 8700 56 36 8 9 18 10 8600 55 38 7 3 6 11 
3 2062 S.RATHINAVEL 8600 60 33 15 10 20 12.2 8400 57 41 2 6 12 12.4 
4 2061 S.INDHU 8000 67 25 8 8 15 11.3 8200 63 33 4 4 8 11.8 
5 2089 M.KAVIYA 8400 53 40 7 8 16 10 8200 56 49 5 2 4 12 
6 2197 A.RITHICK 8800 62 22 16 11 22 12.3 8600 58 38 4 6 12 12.6 
7 2198 A.MANO AADHVICK 8400 57 33 10 7 14 11.2 8000 64 33 3 4 8 11.5 
8 2244 S.SRI MAHALAKSHMI 8600 53 43 4 7 15 9.8 8300 55 42 3 2 4 10.2 
9 2431 KRITHIGA 8600 61 23 16 10 20 12.2 7600 58 39 3 5 10 12.3 
10 2465 S.MAHESHWARAN 8700 56 34 10 8 16 11.2 8400 61 35 4 2 4 11.6 
11 2835 S.AKIM 8900 54 40 6 9 18 9.6 8100 56 40 4 3 6 10.8 
12 169 N.ISTHAR PARK 8700 61 23 16 11 22 12.4 8100 56 37 7 4 8 12.4 
13 171 S.ABINAYA SARASWATHY 8900 57 33 10 12 24 11.4 8600 52 46 2 3 6 11.4 
14 225 IRPHANA 8800 56 34 6 11 22 9.8 8300 49 36 15 5 10 9.8 
15 369 JEFRIN 8800 62 23 17 12 24 12.5 8500 53 43 4 3 6 12.5 
16 370 JESLIN 8900 66 24 10 13 26 11.8 8900 59 38 3 7 14 11.8 
17 680 JOSEPH 8600 56 30 14 13 26 9.8 8400 54 39 7 10 20 10.9 
18 681 FENISTA 9000 62 22 16 13 26 12.2 8500 58 40 2 3 6 12.2 
19 688 ANUSHYA 8700 50 35 15 13 26 13.4 8100 59 33 8 6 12 13.2 
20 689 POORVIKA 8600 53 43 4 12 24 12.8 8300 54 42 4 2 4 12.6 
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INVESTIGATIONS OF 20 INPATIENTS OF LASUNATHABITHAM 
 
SL.NO 
 
IP 
NO. 
 
Name of the patient 
URINE ANALYSIS MOTION ANALYSIS 
       Before Treatment       After Treatment   BeforeTreatment After Treatment 
Alb Sug Dep Alb Sug Dep Ova Cyst Ova Cyst 
1 1409 L.VISHNU Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
2 1410 L.ELAKKIYA Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
3 2062 S.RATHINAVEL Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
4 2061 S.INDHU Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
5 2089 M.KAVIYA Nil Nil 1-2 Epithelial cells Nil Nil NAD Nil Nil Nil Nil 
6 2197 A.RITHICK Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
7 2198 A.MANO AADHVICK Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
8 2244 S.SRI MAHALAKSHMI Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
9 2431 KRITHIGA Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
10 2465 S.MAHESHWARAN Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
11 2835 S.AKIM Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
12 169 N.ISTHAR PARK Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
13 171 S.ABINAYA SARASWATHY Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
14 225 IRPHANA Nil Nil 1-2 pus cells Nil Nil NAD Nil Nil Nil Nil 
15 369 JEFRIN Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
16 370 JESLIN Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
17 680 JOSEPH Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
18 681 FENISTA Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
19 688 ANUSHYA Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
20 689 POORVIKA Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
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CASE REPORT OF 20 INPATIENTS OF LASUNATHABITHAM 
 
S.No IP.No Name Age/Sex Duration of illness/days Signs and Symptoms Admission Discharge Results 
1 1409 L.VISHNU 12/MC 4 
Pain in throat, Nasal discharge, Hoarseness of 
voice, Difficult to swallow, Difficult to breath, 
Fever. 
O/E, Cervical lymphadenitis on Rt side, 
Halitosis present. 
28.5.2018 11.6.2018  Good 
2 1410 L.ELAKKIYA 7/FC 7 
Pain in throat, Cough without expectoration, 
Hoarseness of voice, Difficult to swallow, 
Difficult to breath, Rt ear pain. 
O/E, Cervical lymphadenitis on both side, 
Halitosis present. 
28.5.2018 11.6.2018 Moderate 
3 2062 S.RATHINAVEL 5/MC 12 
Pain in throat, Nasal discharge, Hoarseness of 
voice, Difficult to swallow, Difficult to breath, 
Snoring. 
O/E, Cervical lymphadenitis, Halitosis not 
present. 
11.8.2018 29.8.2018  Good 
4 2061 S.INDHU 9/FC 6 
Pain in throat, Nasal discharge, Hoarseness of 
voice, Difficult to swallow, Difficult to breath, 
Fever. 
O/E, Cervical lymphadenitis on Lt side, 
Halitosis present. 
11.8.2018 29.8.2018 Moderate 
5 2089 M.KAVIYA 6/FC 10 
Pain in throat, Cough without expectoration, 
Hoarseness of voice, Difficult to swallow, 
Difficult to breath, Lt ear pain, Constipation. 
O/E, Cervical lymphadenitis on Lt side, 
Halitosis present. 
 
 
15.8.2018 29.8.2018 Moderate 
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6 2197 A.RITHICK 7/MC 14 
Pain in throat, Nasal discharge, Hoarseness of 
voice, Difficult to swallow, Difficult to breath, 
Snoring. 
O/E, Cervical lymphadenitis, Halitosis not 
present. 
27.8.2018 10.9.2018 Good 
7 2198 A.MANO AADHVICK 9/MC 4 
Pain in throat, Nasal discharge, Hoarseness of 
voice, Difficult to swallow, Difficult to breath, 
Fever. 
O/E, Cervical lymphadenitis on Lt side, 
Halitosis present. 
27.8.2018 10.9.2018  Good 
8 2244 S.SRI MAHALAKSHMI 5/FC 15 
Pain in throat, Cough without expectoration, 
Hoarseness of voice, Difficult to swallow, 
Difficult to breath, Rt ear pain, Constipation. 
O/E, Cervical lymphadenitis on Rt side, 
Halitosis present. 
01.9.2018 15.9.2018 Good 
9 2431 KRITHIGA 8/FC 5 
Pain in throat, Nasal discharge, Hoarseness of 
voice, Difficult to swallow, Difficult to breath, 
Snoring. 
O/E, Cervical lymphadenitis, Halitosis not 
present. 
26.9.2018 10.10.2018  Good 
10 2465 S.MAHESHWARAN 10/MC 5 
Pain in throat, Nasal discharge, Hoarseness of 
voice, Difficult to swallow, Difficult to breath, 
Fever. 
O/E, Cervical lymphadenitis on Rt side, 
Halitosis not present. 
29.9.2018 13.10.2018  Good 
11 2835 S.AKIM 6/MC 20 
Pain in throat, Cough without expectoration, 
Hoarseness of voice, Difficult to swallow, 
Difficult to breath, Lt ear pain, Constipation. 
O/E, Cervical lymphadenitis on Lt side, 
Halitosis not present. 
 
19.11.2018 2.12.2018  Good 
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12 169 N.ISTHAR PARK 8/FC 10 
Pain in throat, Nasal discharge, Hoarseness of 
voice, Difficult to swallow, Difficult to breath, 
Snoring. 
O/E, Cervical lymphadenitis, Halitosis not 
present. 
26.1.2019 09.2.2019  Moderate 
13 171 S.ABINAYA SARASWATHY 10/FC 7 
Pain in throat, Nasal discharge, Hoarseness of 
voice, Difficult to swallow, Difficult to breath, 
Fever. 
O/E, Cervical lymphadenitis on Lt side, 
Halitosis not present. 
26.1.2019 09.2.2019 Moderate 
14 225 IRPHANA 12/FC 15 
Pain in throat, Cough without expectoration, 
Hoarseness of voice, Difficult to swallow, 
Difficult to breath, Rt ear pain, Constipation. 
O/E, Cervical lymphadenitis on Rt side, 
Halitosis not present. 
01.2.2019 14.2.2019 Good 
15 369 JEFRIN 9/MC 12 
Pain in throat, Nasal discharge, Hoarseness of 
voice, Difficult to swallow, Difficult to breath, 
Snoring. 
O/E, Cervical lymphadenitis, Halitosis not 
present. 
14.2.2019 27.2.2019 Good 
16 370 JESLIN 5/FC 5 
Pain in throat, Nasal discharge, Hoarseness of 
voice, Difficult to swallow, Difficult to breath, 
Fever. 
O/E, Cervical lymphadenitis on Lt side, 
Halitosis  present. 
14.2.2019 27.2.2019 Moderate 
17 680 JOSEPH 9/MC 8 
Pain in throat, Cough without expectoration, 
Hoarseness of voice, Difficult to swallow, 
Difficult to breath, Lt ear pain, Constipation. 
O/E, Cervical lymphadenitis on Lt side, 
Halitosis not present. 
 
16.3.2019 29.3.2019 Good 
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From this study, Out of 20 Patients 14 Patients (70%) had good Relief, 6 Patients (30%) had moderate relief. 
 
 
 
 
  
18 681 FENISTA 5/FC 12 
Pain in throat, Nasal discharge, Hoarseness of 
voice, Difficult to swallow, Difficult to breath, 
Snoring. 
O/E, Cervical lymphadenitis, Halitosis not 
present. 
16.3.2018 29.3.2018 Good 
19 688 ANUSHYA 12/FC 7 
Pain in throat, Nasal discharge, Hoarseness of 
voice, Difficult to swallow, Difficult to breath, 
Fever. O/E, Cervical lymphadenitis, Halitosis 
not present. 
18.3.2019 01.4.2019 Good 
20 689 POORVIKA 7/FC 10 
Pain in throat, Cough without expectoration, 
Hoarseness of voice, Difficult to swallow, 
Difficult to breath, Rt ear pain, Constipation. 
O/E, Cervical lymphadenitis, Halitosis not 
present. 
18.3.2019 01.4.2019 Good 
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THROAT SWAB CULTURE : 20 INPATIENTS OF LASUNATHABITHAM 
 
 
S.No 
 
IP.No 
 
      Name 
 
Age/Sex 
 
Before Treatment After Treatment 
 
Present Culture (Micro organism In Throat) 
 
Present Culture 
1 1409 L.VISHNU 12/MC Streptococcus pneumonia Nil 
2 1410 L.ELAKKIYA 7/FC Streptococcus pneumonia Nil 
3 2062 S.RATHINAVEL 5/MC Streptococcus pneumonia Nil 
4 2061 S.INDHU 9/FC Streptococcus pneumonia Nil 
5 2089 M.KAVIYA 6/FC Staphylococcus aureus Nil 
6 2197 A.RITHICK 7/MC Streptococcus pneumonia Nil 
7 2198 A.MANO AADHVICK 9/MC Staphylococcus aureus Nil 
8 2244 S.SRI MAHALAKSHMI 5/FC Streptococcus pneumonia Nil 
9 2431 KRITHIGA 8/FC Streptococcus pneumonia Nil 
10 2465 S.MAHESHWARAN 10/MC Streptococcus pneumonia Nil 
11 2835 S.AKIM 6/MC Staphylococcus aureus Nil 
12 169 N.ISTHAR PARK 8/FC Streptococcus pneumonia Nil 
13 171 S.ABINAYA SARASWATHY 10/FC Streptococcus pneumonia Nil 
14 225 IRPHANA 12/FC Streptococcus pneumonia Nil 
15 369 JEFRIN 9/MC Streptococcus pneumonia Nil 
16 370 JESLIN 5/FC Staphylococcus aureus Nil 
17 680 JOSEPH 9/MC Streptococcus pneumonia Nil 
18 681 FENISTA 5/FC Streptococcus pneumonia Nil 
19 688 ANUSHYA 12/FC Streptococcus pneumonia Nil 
20 689 POORVIKA 7/FC Streptococcus pneumonia Nil 
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ABSOLUTE EOSINOPHIL COUNT 
 
S.No IP No Name Age/Sex Before Treatment Cells/Cu mm 
AfterTreatment 
Cells/Cu mm 
1 1409 L.VISHNU 12/MC 360 320 
2 1410 L.ELAKKIYA 7/FC 400 360 
3 2062 S.RATHINAVEL 5/MC 410 310 
4 2061 S.INDHU 9/FC 350 290 
5 2089 M.KAVIYA 6/FC 340 300 
6 2197 A.RITHICK 7/MC 410 310 
7 2198 A.MANO AADHVICK 9/MC 380 290 
8 2244 S.SRI MAHALAKSHMI 5/FC 420 330 
9 2431 KRITHIGA 8/FC 390 240 
10 2465 S.MAHESHWARAN 10/MC 450 360 
11 2835 S.AKIM 6/MC 210 210 
12 169 N.ISTHAR PARK 8/FC 480 290 
13 171 S.ABINAYA SARASWATHY 10/FC 350 200 
14 225 IRPHANA 12/FC 440 310 
15 369 JEFRIN 9/MC 360 250 
16 370 JESLIN 5/FC 380 170 
17 680 JOSEPH 9/MC 510 400 
18 681 FENISTA 5/FC 450 300 
19 688 ANUSHYA 12/FC 390 210 
20 689 POORVIKA 7/FC 420 280 
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HEMATOLOGICAL INVESTIGATIONS : 20 OUT PATIENTS OF LASUNATHABITHAM 
 
 
S.NO 
 
OP NO 
 
Name of the patient 
                                      HEMATOLOGICAL INVESTIGATIONS 
                      Before   Treatment             After Treatment 
TCL 
Cumm 
DC% ESR 
mm 
 
HB 
gms% 
TCL 
Cum
m 
DC% ESR mm  
HB   
gms% P L E ½ 
hr 
1 
hr 
P L E ½ 
hr 
1 hr 
1 4350 Selvaharish 7800 61 30 9 12 24 10.4 7600 59 34 7 4 8 10.8 
2 44044 Oviya 8200 57 33 10 2 4 11.2 8200 56 35 9 2 4 11.5 
3 45085 Esakkimuthu 7900 55 34 11 12 24 10.4 8100 52 40 8 7 14 11 
4 47747 K.Priya 8400 53 38 9 14 27 10.8 8300 54 40 6 7 14 10.5 
5 48075 Dhivya 8200 56 36 8 9 18 10 8200 57 37 6 5 10 10.7 
6 48377 Senthamizh 8900 57 33 10 12 24 11.4 8600 52 46 2 3 6 11.4 
7 54082 Palanisaranya 7000 66 30 4 5 10 10.7 7100 65 30 5 4 8 11.3 
8 55525 Saja 8300 56 32 12 3 6 9.5 8200 61 33 6 2 5 10.9 
9 60699 Serina 8200 56 41 3 4 9 10.4 8200 56 41 3 2 4 11 
10 60670 Suriya 8100 51 45 4 3 6 11 8000 55 45 3 3 6 11.6 
11 61601 Esakki srinivasan 7800 56 44 2 3 7 10.8 7700 56 42 4 2 4 11.2 
12 62836 Sabia 8300 51 34 15 5 10 10 8200 56 34 10 4 8 10.8 
13 63351 Syyed alifathima 8100 56 31 13 4 9 11 8000 57 34 9 3 6 10.6 
14 67189 Siddhika 9800 78 20 2 7 15 8.5 9800 61 35 4 4 7 9 
15 69695 Bency 8100 57 37 6 10 20 9.8 8000 57 38 5 8 16 10 
16 78642 Mathan 8500 51 45 4 4 7 10.2 8500 52 45 5 4 8 10.6 
17 79266 Maharajan 8600 50 40 10 9 18 11.2 8500 51 42 7 5 10 11.6 
18 79395 Muralidharan 7800 50 48 2 6 12 12.1 7800 52 46 2 4 8 12.3 
19 79418 Vadivu 8000 52 42 6 11 22 10.2 8000 56 41 3 7 14 11.8 
20 81488 Keerthana 7600 56 36 8 12 25 11.9 7600 58 36 6 8 16 12 
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INVESTIGATIONS OF 20 OUT PATIENTS OF LASUNATHABITHAM 
 
S.NO 
 
OP NO. 
 
Name of the patient 
 
URINE ANALYSIS 
 
MOTION ANALYSIS 
Before Treatment After Treatment BeforeTreatment After Treatment 
Alb Sug Dep Alb Sug Dep Ova Cyst Ova Cyst 
1 4350 Selvaharish Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
2 44044 Oviya Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
3 45085 Esakkimuthu Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
4 47747 K.Priya Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
5 48075 Dhivya Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
6 48377 Senthamizh Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
7 54082 Palanisaranya Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
8 55525 Saja Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
9 60699 Serina Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
10 60670 Suriya Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
11 61601 Esakki srinivasan Nil Nil 1-2 Epithelial cells Nil Nil NAD Nil Nil Nil Nil 
12 62836 Sabia Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
13 63351 Syyed alifathima Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
14 67189 Siddhika Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
15 69695 Bency Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
16 78642 Mathan Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
17 79266 Maharajan Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
18 79395 Muralidharan Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
19 79418 Vadivu Nil Nil 1-2 pus cells Nil Nil NAD Nil Nil Nil Nil 
20 81488 Keerthana Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
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Case Report : 20 outpatients of Lasunathabitham 
 
S.No OP.NO PATIENT NAME AGE/SEX No.of days treated Result 
1 4350 Selvaharish 12/MC 14 Moderate 
2 44044 Oviya 8/FC 14 Good 
3 45085 Esakkimuthu 12/MC 18 Moderate 
4 47747 K.Priya 12/FC 14 Good 
5 48075 Dhivya 8/FC 12 Good 
6 48377 Senthamizh 7/MC 14 Good 
7 54082 Palanisaranya 9/FC 14 Good 
8 55525 Saja 7/FC 14 Good 
9 60699 Serina 9/FC 14 Good 
10 60670 Suriya 7/MC 11 Good 
11 61601 Esakki srinivasan 5/MC 14 Moderate 
12 62836 Sabia 7/FC 10 Good 
13 63351 Syyed alifathima 10/FC 14 Good 
14 67189 Siddhika 8/FC 10 Good 
15 69695 Bency 5/FC 8 Good 
16 78642 Mathan 11/MC 14 Moderate 
17 79266 Maharajan 12/MC 8 Good 
18 79395 Muralidharan 12/MC 20 Good 
19 79418 Vadivu 5/FC 14 Good 
20 81488 Keerthana 7/FC 10 Good 
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10. DISCUSSION 
Lasunathabitham is one of the Respiratory problem in paediatric age group, 
the clinical features of which are clearly described in various siddhar’s text. This 
disease most probably correlates with Tonsillitis in modern science. 
In this study 40 cases were treated at the post graduate department of 
Kuzhandhai Maruthuvam. Siddha methods of diagnosis were carried out and recorded 
in the selection proforma, and the diagnosis was confirmed with the help of modern 
investigations. The patients were treated with the drug Sugantha Malli Chooranam 
and clearly observed. The results and observations are discussed here. 
1. Distribution according to age: 
This study indicates the children’s under the age group of 5 to 12 years were 
commonly affected, since they contributed to school going age group, 
overpopulation of the children had high extent of tonsillar infection. 
2. Distribution according to sex: 
Among 40 cases of study 60% were female children and 40% were male 
children. 
3. Distribution according to socio economic status: 
The patients affected by Lasunathabitham, 25% of cases belonged to low 
income group and 75% of cases belonged to middle income group. Due to 
poverty, overpopulation and unhygienic practices which are all of this disease was 
more prevalent among the poor and the middle class. 
4. Distribution of paruva kaalangal: 
According to paruva kaalangal the highest distribution of cases 35% was 
noticed in Kaar kaalam and 25% of patients were affected in Muthuvenil kaaalam. 
5. Diet history: 
According to diet history, 80% of cases had mixed diet and 20% had 
vegetarian diet. The highest incidence of cases were observed in mixed diet of 
food habits. 
6. Family History: 
According to family history, 90% of the cases had negative family history, and 
10% of the case had positive family history. The higher incidence of cases had no 
relvant family history. 
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7. Distribution of Land: 
Among the selected cases 80% of them were from Marutham land and 20% of 
them were from Neithal land. According to the siddha concept Marutham land does 
not produce any disease. But due to altered life style and environmental condition the 
incidence of this disease occurs in land of Marutham and Neithal land. 
8. Distribution according to Uyir thathukkal: 
a) Derangement of Vatham: 
Due to derangement of vatham, the following symptoms may occur. Pranan 
was deranged in 100% of cases and it causes difficulty in breathing. Abanan (30%) 
causes constipation in some patients. Viyanan (100%) causes fatigue, Uthanan 
(100%) causes cough and wheezing in some patients. Samanan (100%) causes 
difficult in controlling other vathams, Kirukaran was deranged in 100% of cases, 
cause loss of appetite, cough, running nose and Devathathan (100%) cause tiredness 
in some cases. 
b) Derangement of Pitham: 
Anilapitham was deranged in 30% of patients causing indigestion. 
Ranjakapitham was deranged in 30% of patients due to malnutrition and pallor, 
Saathapitham was dearanged in 100% of patients causing limitations in their daily 
physical activities. 
c) Derangements of Kabam:  
Due to derangements of Kabam, Avalambagam was deranged in 100% of 
patients causing difficulty in breathing.  
9. Distribution according to Ezhu Udal Kattugal: 
In ezhu udal kattugal, saaram (100%) senneer (30%), oon (100%) were 
affected  causing General Fatigue, Anaemia, and swelling of the tonsils. 
10. EnVagai Thervugal: 
According to this study, 45% of cases had pithakabam naadi, 35% of cases 
had kabapitha naadi, 10% 0f cases had pithavatha naadi5% of cases had vathapitha 
naadi 5% of cases had kabavatha naadi. Sparisam was affected in 25% of cases 
(Fever), Naa was affected in 30% of cases (coated and pallor) Niram was altered in 
100% of cases due to Redness of Tonsil. Mozhi was affected in 100% of cases due to 
hoarseness of voice, vizhi was affected in 30% of patients due to pallor. Malam was 
altered in 30% due to constipation and  Mothiram was  not altered in any cases. 
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11. Nei Kuri: 
In this study most of the patients had Kaba Neer (52.5%) which stood as a 
pearl indicating that the most predominant manifestation of the lasunathabitham is 
Kabam. 
12. Distribution according to aetiological factors: 
Intake of cold food stuff, cooldrinks, Ice cream, etc., contribute to 87.5% of 
cases. Seasonal variations contribute to 75%, Drinking contaminated water contribute 
to 50% of cases and Living in congested areas, using same vessels by many, 
contribute to 25% of cases.  
13. Distribution of clinical features:  
Before treatment almost all cases (100%) were presented with sore throat, 
redness and swelling of the tonsil and after treatment it was reduced to 10%. Before 
treatment, 87.5% of cases had cough and after treatment it reduced to 5%. Before 
treatment, 87.5% of cases had dysphagia and  hoarseness of voice, after treatment  it 
reduced to 5%. Before treatment, 75% of cases had cervical lymphadenitis  and after 
treatment  it reduced to 7.5%. Before treatment, 35% of patients had Nasal congestion 
and Nasal discharge  and after treatment it reduced to 2.5%. Before treatment 50% of 
patients had fever and after treatment it reduced to 2%. Before treatment, 37.5% of 
patients had constipation and after treatment it reduced to 1%. Before treatment, 5% 
of cases had Nausea and 25% of cases had Halitosis and after treatment  it reduced to 
0%. Before treatment, 12.5% of cases had headache and after treatment it reduced to 
0% .Almost all the signs and symptoms were decreased after treatment 
14. Lab Investigations: 
 Routine Examination of blood, urine and motion were done before and after 
treatment. In blood investigation most of the cases (75%) elevated ESR and 
eosinophil count was decreased after treatment. 
 Throat swab were don on before and after treatment.  In most of the cases 
streptococcus pneumoniae were present in throat swab.  After treatment there 
is no bacterial growth in throat swab culture. 
 
15. Biochemical Analysis: 
Qualitative analysis of the trial drug Sugantha Malli Chooranam revealed 
the presence of ferrous iron which is more soluble and readily absorbable form 
that in treating children who are associated with anaemia. The study also indicates 
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the presence of Calcium, Sulphate, Chloride, Starch, Reducing Sugar and Amino 
acid etc., which are all brings about the therapeutic action in bone mineralisation, 
electrolyte balance, muscle growth, enhancement of haemoglobin level, kills the 
pathogen like virus and bacteria, wound healing activity and regulate the immune 
system in body. 
16. Antibacterial Activity: 
Antibacterial activity of Sugantha Malli Chooranam showed that it inhibited the 
growth of bacterial strains of Staphylococci aureus, Streptococci pneumoniae, 
Pseudomonas aeruginosa and Escherichia coli. 
17. Pharmacological Analysis: 
Pharmacological Analysis showed the trial drug Sugantha Malli Chooranam 
has significant Anti – inflammatory and Analgesic activity. 
18. RESULT: 
Satisfactory improvement was reported in 14 days of commencement of 
treatment. Out of 40 cases 30 patients (75%) showed Good response with 
remarkable relief of symptoms, frequency of similar episodes is reduced. Moderate 
result was observed in 10 cases (25%) with decreased in signs and symptoms. 
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11. SUMMARY 
 The aim of this dissertation subject is to assess the efficacy of trial drug 
“Sugantha Malli Chooranam” for “Lasunathabitham” without any adverse 
effects. 
 Sufficient literatures with reference to Lasunathabitham was not found in siddha 
system. Hence from the available texts, signs, symptoms and characteristic 
features were collected and the medicine was choosen for the study. 
 The Etiopathogenesis and symptoms of Lasunathabitham have been correlated 
with that of Tonsillitis with evidence of literature. 
 Clinical diagnosis and selection of cases was based on clinical features 
described in Kuzhanthai Maruthuvam text book. 
 Laboratory diagnosis was done by modern methods of examination. 
 20 cases were selected and treated in IPD, Department of Kuzhanthai 
Maruthuvam, Government siddha medical college and hospital, Palayamkottai 
for the clinical study. 
 The medicine choosen for treatment and management of Lasunathabitham was 
Sugantha Malli Chooranam (2 gms) Internal, thrice a day. 
 The trial drug selection is based on its siddha pathological and pharmacological 
action to rectify the deranged Mukuttram and also due to its Anti-inflammatory, 
Analgesic effect of ingredients. 
 All the children were kept under strict dietary control during the treatment. The 
observation on effect of therapy was encouraging. 
 The documentation of observation made during the clinical study showed that 
the drug Sugantha Malli Chooranam is clinically effective. 
 The Biochemical analysis of the trial drug had ferrous iron which adds to the 
clinical prognosis of Lasunathabitham by Sugantha Malli Chooranam. The 
study also indicates the presence of Calcium, Sulphate, Chloride, Starch, 
Reducing Sugar and Amino acid etc., which are all brings about the therapeutic 
action in bone mineralisation, electrolyte balance, muscle growth, enhancement 
of haemoglobin level, kills the pathogen like virus and bacteria, wound healing 
activity and regulate the immune system in body. 
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 Anti bacterial activity of Sugantha Malli Chooranam showed that it resistant the 
growth of bacterial strain against Staphylococci aureus, Streptococci 
pneumoniae, Pseudomonas aeruginosa and Escherichia coli. 
 In pharmacological analysis, the trial medicine Sugantha Malli Chooranam had 
siginificant Anti – inflammatory, Analgesic action which help to improve the 
patients quality of life. 
 With there benefits “Sugantha Malli Chooranam” can be deemed as an effective 
drug for “Lasunathabitham” (Tonsillitis). 
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12. CONCLUSION 
 
 The Global burden of Tonsillitis in children increasing prevalence and its 
impact in reducing the quality of life in children has prompted the author to 
choose an effective drug without any side effects, it is believed to improve 
the quality of life in children. 
 The trial drug is safe to the children. 
 The treatment of Lasunathabitham with Sugantha Malli Chooranam has 
showed Good response with no adverse effect and ensure to be safe, effective 
and simple to administration. 
 The trial drug Sugantha Malli Chooranam is in easy form of preparation. 
 The ingredients of trial drug are feasible and useful, these compounds may 
serves as potentially useful drug at lower cost. 
 Clinical results were found to be significant good improvement was found in 
75% of cases, Moderate in 25% of cases. 
Therefore it is concluded that the trial drug “Sugantha Malli 
Chooranam” along with the modalities of Pranayama proves to be excellent 
in attack the tonsillitis among children. 
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ANNEXURE - II 
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “LASUNATHABITHAM” –  
 A PEDIATRIC DISORDER AND THE DRUG OF CHOICE IS  
SUGANTHA MALLI CHOORANAM 
Form 1-SCREENING & SELECTION PROFORMA                                                                                          
1. S.I.No:     2.OP/IP No:    3.Name: 
4. Age:    5.Gender:     6.Date of Enrollment: 
7. Date of Completion:     8. Information:  
INCLUSION  CRETERIA:        YES         NO  
• Age 5-12 years. 
• Sex - Male and Female Children 
• Throat pain 
• Dysphagia 
• Hoarseness of voice 
• Enlarged tonsils 
• Referred pain in the ear 
• Malaise 
• Mild Fever with tonsillitis      
EXCLUSION CRITERIA: 
• Congenital anomaly of pharynx 
• Known case of pulmonary Tuberculosis 
• Physiological hyperplasia of lymphoid follicles 
• Mailgnancy 
• Tonsillitis which have indication for surgery 
 
Signature of Guide:                Signature of Investigator:  
 
Signature of HOD:  
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI  
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “LASUNATHABITHAM”- 
 A PEADIATRIC DISORDER AND THE DRUG OF CHOICE IS  
SUGANTHA MALLI CHOORANAM 
 
FORM IA – HISTORY PROFORMA ON ENROLLMENT 
 
Patient id: OP/IP NO. VISIT DATE (___/____/_____) 
NAME :  
AGE:  
Gender:   MALE           FEMALE  Date Of Birth :( ____/____/_____)   
Fathers/Mother/Guardian name :  
Fathers Occupation:  
Fathers Monthly income:  
Religion:  
Socioeconomic status:  
Patient informant :  
 
 
 
 
 
 
 
 
1. Complaints and duration  
 
 
 
2. Present illness  
 
Postal Address  
 
 
Contact no : 
  
xvii 
 
History of past Illness 
History /Symptoms /Signs   Yes  No  if, Yes Details  
Any Similar Complaints      _____________ 
Bronchial Asthma       _____________ 
Dust Allergy        _____________ 
Hospitalization        _____________ 
Any Other         _____________ 
 
Family History       
Any hereditary familial Disease    Yes  No 
If yes, details………………………………………………………………………….. 
 
Immunization History  
Proper Immunization given   Yes  No …………………….. 
 
Food Habits:  
1. Veg   2. Non-Veg   3. Mixed  
 
General assessment                            Yes  No 
1. Picca 
2. Nail Biting 
3. Bowel Movements  
 
General Examination   Yes  No    
1. Pallor       
2. Jaundice        
3. Cyanosis         
4. Clubbing         
5. Pedal oedema         
6. Lymph adenopathy         
 
 
Vital signs:- 
1. Pulse rate / mint 
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2. Heart rate / mint 
3. Respiratory Rate / mint 
4. Temperature 
5. BP 
 
Anthropometry: 
 Height 
Weight 
Head Circumference 
Chest Circumference 
Mid Arm Circumference 
 
CLINICAL EXAMINATION: 
Other Systems:            Normal    Affected 
 Cardio Vascular system:        
 Gastro intestinal system:        
 Masculo skeletal system:        
 Central nervous system:        
 Endocrine system:        
 
Nilam:  
Kurinji  Mullai    Marutham  Neithal    Paalai 
 
Kaala Iyalbu 
Kaarkalam   Koothirkaalam Munpanikaalam 
Pinpanikaalam Illavenikaalam Muthuvenrkaalam 
 
Yaakai 
 
Vatham  Vatha Pitham  Vatha Kabam 
 
Pitham   Pitha Vatham  Pitha Kabam 
 
Kabam   Kaba Vatham  Kaba Pitham 
  
  
  
  
  
  
     
  
 
 
 
 
   
   
   
  
xix 
 
Uyir Thathukkal 
Vatham 
  Normal Affected  Remarks  
Pirannan 
Abanan 
Uthanan 
Viyanan 
Samanan 
Nagan 
Koorman 
Kirujaran 
Devathathan 
Dhanajeyan 
 
Pitham 
     Normal  Affected  Remarks  
Analam 
Ranjagam 
Saathagam 
Alosagam 
Prasagam 
 
Kabam 
     Normal   Affected  Remarks  
Avalambagam 
Kilethagam 
Pothngam 
Tharpagam 
Santhigam 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
xx 
 
Udalthathukkal 
      Normal    Affected  Remarks  
Saaram 
Senneer 
Oon 
Kolupu 
Enbu 
Moolai 
Sukilam/Suronitham 
 
Envagai Thervugal 
Naa 
Niram 
Mozhi 
Vizhi 
Sparisam 
 
Malam 
Niram 
Edai 
Erugal 
Elagal 
 
Moothiram 
Neerkuri:   
Niram  Normal      Affected 
Edai  Normal   Affected 
Nurai  Normal   Affected 
Manam Normal   Affected 
 Enjai  Normal   Affected  
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Neikuri: 
 Vatham 
 Pitham 
 Kabam 
 Others 
 
Naadi: 
Thani Nadi 
 Vadhan  Pitham   Kabam  
 
Thontha Nadi 
 Vatha Pitham  Pitha vatham         Pitha Kabam     Kaba pitham 
 
 
Diagnosis__________________________________ 
Admitted to trial : 1. Yes   2. No. 
if yes, S.No:  1IP   2.OP 
 
Diagnosis: 
DRUG ISSUED:______________ 
Date :________________________ 
Station _______________________ 
 
 
Date :      
 
Signature of the Guide        Signature of Principal Investigator: 
 
Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
BRANCH IV – KUZHANTHAI MARUTHUVAM 
PALAYAMKOTTAI - 627 002. 
FORM-IB: CASE SHEET PROFORMA-“LASUNATHABITHAM” 
 
 
 
 
 
 
 
 
             
Religion: 
       
        
        
 
 
 
 
 
 
 
     
  
I.P.No : 
 
Bed. No : 
 
Name of the Medical unit: 
 
Name : 
 
Age/Sex: 
 
Permanent Address: 
 
 
 
 
Temporary Address: 
PG-Pediatric Ward - IPD, Government 
Siddha Medical College and Hospital, 
Palayamkottai. 
Informant: 
 
Invesitgator: 
 
 
 
 
Nationality: 
 
Religion: 
 
Occupation  (Parents): 
 
Income: 
 
Date of Admission: 
 
 
Date of  Discharge: 
 
 
Diagnosis: 
 
 
 
 
 
 
 
 
 
 
Medical Officer: 
  
xxiii 
 
Complaints and duration : 
 
 
 
History of present illness : 
 
 
 
History of past illness : 
 
 
Personal History: 
 
 
Family History: 
 
Consanguinity    : 
 Ataxia     : 
 Blindness    : 
 CP     : 
 MR     : 
 Seizure    : 
 Movement disorder   : 
 Deafness    : 
  
Socio-Economic Status: 
 
Habits: 
 Bowel and micturation habit  : 
 Sleep     : 
 Enuresis    : 
 Thumb sucking   : 
 Nail biting    : 
 Pica     : 
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Diet History : 
 Appetite    : 
 Types of diet    : 
 
Antenatal History : 
 Medication    : 
 Infection (STARCH)   : 
 Irradiation    : 
 Toxaemia    : 
 Hemorrhage    :  
 Severe Anaemia   : 
 Eclampsia    : 
 H/o Decreased foetal Movements : 
 
 Maternal malnutrition   : 
 Maternal Diabetes Mellitus(DM) : 
 Maternal Hypertension  : 
 
Natal: 
 Breech presentation   : 
 Forceps / - C- Section   : 
 Home / Hospital   : 
 H/o prolonged labour   : 
 
Post Natal 
 Post partum Haemorrhage  : 
 Sepsis     : 
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Neonatal History: 
 Birth Weight    : 
 Term / Pre term baby   : 
 Congenital malformations  : 
 Birth Asphyxia – APGAR – Score : 
 Neonatal convulsions   : 
 Kernicterus    : 
 Diarrhoea    : 
 Birth injury / Head injury / Activity of the child 
a) at birth   : 
b) after birth   : 
Time of cry after birth  : 
Resusscitation done or not  : 
(if done nature of resusscitation) 
Respiratory distress / cyanosis : 
Fever / altered sensorium  : 
Feeding after birth   : 
Lymphadenopathy   : 
 
Developmental History : 
 
 
Immunization History : 
 
 
General Examination 
Anthropometry: 
 Height    : 
Weight    : 
Head Circumference   : 
Chest Circumference   : 
Mid Arm Circumference  : 
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1. Consciousness : 
2. Decubitus : 
3. Anemia : 
4. Jaundice : 
5. Cyanosis : 
6. Clubbing : 
7. Pedal oedema : 
8. Lymphadenopathy : 
9. Nourishment : 
10. Skin changes : 
11. Edema: 
12.JVP: 
13.Pulse Rate: 
14.Heart Rate: 
15.Respiratory Rate: 
16.Temperature: 
17.Blood Pressure: 
18.Spine: 
19.Skin: 
Systemic Examination 
Cardio Vascular System: 
Respiratory System: 
Gastro Intestinal System: 
Genito Urinary System: 
Nervous System: 
 Consciousness: 
 Temper Tantrum:  Sociable- Irritable - Playful 
 Memory: 
 Orientation: 
 Speech: 
 Intelligence (I.Q): 
 Handedness: 
 Cranial Nerve Examination: 
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Motor System: 
 Power: 
 Tone: 
 Reflex: 
 Grip: 
 Gate: 
 
Sensory Examination: 
 Superficial Sensation: 
  Touch: 
  Pain: 
  Temperature: 
 Deep Sensation: 
  Position sense: 
  Joint sense: 
  Vibration sense: 
 Cortical Sensation: 
   
 
Cerebellar Signs: 
 
 
Autonomic System: 
 
Siddha Systems – Clinical Examination: 
Nilam 
Kurinchi : 
Mullai : 
Marutham : 
Neithal : 
Palai : 
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Paruva Kaalam 
Kaar : 
Koothir : 
Munpani : 
Pinpani : 
Elavenil : 
Muthuvenil : 
Uyir thathukal: 
Vatham 
Piranan : 
Abaanan : 
Uthaanan : 
Viyaanan : 
Samaanan : 
Naagan : 
Koorman : 
Kirugaran : 
Devathathan : 
Dhananjeyan : 
Pitham 
Analam : 
Ranjagam : 
Sathagam : 
Alosagam : 
Pirasagam : 
Kabam 
Avalambagam : 
Kilethagam : 
Pothagam : 
Tharpagam : 
Santhigam : 
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Udal Kattugal 
Saaram : 
Senneer : 
Oon : 
Kozhuppu : 
Enbu : 
Moolai : 
Sukkilam/Suronitham : 
Ennvagai Thervugal 
Naadi : 
Sparisam : 
Naa : 
Niram : 
Mozhi : 
Vizhi : 
Malam : 
Moothiram : 
Neerkuri 
Niram : 
Manam : 
Nurai : 
Edai : 
Enjal : 
 
Neikuri 
 
 
Malakuri 
Nirami : 
Nurai : 
Edai : 
Erugal : 
Elagal : 
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Lab Investigations 
1. Blood 
 
TC : 
DC : 
Hb : 
ESR : 
Total RBC Count ......................................... Cells / cu.mm 
Absolute Eosinophil Count : 
Differential Count 
 P___%       L___%       E___%      M___%        B___% 
 
2. Urine 
 
Albumin : 
Sugar : 
Deposits : 
 
3. Motion 
 
Ova : 
Cyst : 
Occult blood : 
 
3. Other Investigation : 
 
 Throat Swab Culture : 
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DIFFERNTIAL DIAGNOSIS : 
PROGNOSIS : 
MARUTHUVAMURAI : 
ADVICE : 
DAILY PROGRESS : 
 
 
Date 
 
Symptoms Medicine 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI  
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
 
FORM-II & IIA PRE-CLINICAL AND CLINICAL STUDY ON 
“LASUNATHABITHAM”- A PEDIATRIC DISORDER AND THE DRUG OF CHOICE 
IS SUGANTHA MALLI CHOORANAM 
 
CLINICAL ASSESMENT ON ENROLLMENT DURING AND AFTER TRIAL 
S.I.No: ………….        OP/IP No: …………  Name: ……………… 
Age: …………….         Gender:  …………..   Date of Enrollment: …………. 
Date of Completion :…………. Informant: …………. Reliability :  …………… 
SIDDHA SYSTEM OF EXAMINATION 
 I.ENVAGAI THERVU: [EIGHT-FOLD EXAMINATION] 
1.NAADI: [PULSE PERCEPTION] 
 
 
2.NAA:[TONGUE] 
1  Maa Padithal (Coated tongue)   : 
2. Naavin Niram (Colour of the tongu : 
3. Suvai (Taste Sensation)   : 
4. Vedippu (Fissure)    : 
5. Vai Neer Ooral (Salivation)   : 
6. Deviation     :   
7. Pigmentation    : 
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3.NIRAM: [COMPLEXION] 
 
 
4.MOZHI: [VOICE] 
 
 
5.VIZHI: [EYES] (Lower palpebral conjunctiva) 
 
 
6.MALAM; [BOWEL HABITS / STOOLS] 
 
7. MOOTHIRAM [URINE EXAMINATION] 
 
NEERKURI 1st Day 5th  Day 7th  Day 14th Day 
Niram White/ White/ White/ White/ 
[Colour] Yellowish/ Yellowish/ Yellowish/ Yellowish/ 
 Straw Straw Straw Straw 
 coloured/ Coloured/ coloured/ coloured/ 
 Crystal Crystal Crystal Crystal 
 Clear clear Clear clear 
Manam[Odour] Present/ Absent 
 
Present/ Absent 
 
Present/ Absent 
 
Present/ Absent 
 
 
 
 
 
 
Nurai [Froth] Nil/Reduced/ 
Increased 
Nil/Reduced/ 
Increased 
Nil/Reduced/ 
Increased 
Nil/Reduced/ 
Increased 
Edai 
[Sp.gravity] 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Enjal [Deposits] Present/ Absent Present/ Absent Present/ Absent Present/ Absent 
Volume Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
NEIKURI 1st Day 5th  Day 7th  Day 14th Day 
Serpentine fashion     
Annular/Ringed  fashion     
Pearl beaded fashion     
Mixed fashion     
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8.SPARISAM: [PALPATORY PERCEPTION] 
 
II.THEGI: [TYPE OF BODY CONSTITUTION] 
 
Vatham predominant  Kabam predominant  
Pitham predominant  Thondha udal  
 
III.NILAM: [ LAND WHERE PATIENT LIVED MOST] 
 
     
         Kurinji         Mullai  Marutham   Neithal             Palai 
    (Hilly terrain)      (Forest range)             (Plains)             (Coastal belt)  (Arid regions) 
 
IV.KAALAM: 
Kaarkalam -   Pinpanikalam - 
Koothirkalam -   Ilavenil - 
Munpanikalam -   Muthuvenil - 
 
 
V.MUKKUTRAM:[AFFECTION OF THREE HUMORS]  
A)VATHAM: 
 1st Day 5th  Day 7th  Day 14th Day 
Praanan     
Abaanan     
Viyaanan     
Udhaanan     
Samanan     
Naagan (Higher intellectual function)     
Koorman (airway of yawning)     
Kirukaran(Air of salivation/nasal  
secrection) 
    
Devathathan (Air of laziness)     
Dhananjeyan(this air that acts on death)     
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B.PITHAM: 
 
 1st Day 5th  Day 7th  Day 14th Day 
Analpitham (Gastric juice)     
Ranjagam (Haemoglobin)     
Saathagam (Life energy)     
Praasagam (Bile)     
Aalosagam     
     
C.KABAM: 
  
 1st Day 5th  Day 7th  Day 14th Day 
Avalambagam (Serum)     
Kilaethagam (saliva)     
Pothagam (lymph)     
Tharpagam(cereb rospinal fluid)     
Santhigam (synovial fluid)     
  
VI.SEVEN DHATHUS: (7 SOMATIC COMPONENTS) 
 1st Day 5th  Day 7th  Day 14th Day 
Saaram [Chyme]     
Senneer [Blood]     
Oon [Muscle]     
Kozhuppu [Fat]     
Enbu [Bones]     
Moolai [Bonemarrow]     
Sronitham[Genital  discharges]     
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1.SYSTEMIC EXAMINATION: 
 
 1st Day 5th  Day 7th  Day 14th Day 
1)Gastrointestinal  System     
2) Respiratory System     
3)Cardiovascular  System     
4)Central Nervous System     
5)Urogenital System     
 
 
2. GENERAL EXAMINATION: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 1st Day 5th  Day 7th  Day 14th Day 
Height (cms)     
Weight (kg)     
Head Circumference     
Chest Circumference     
Mid Arm Circumference     
Temperature (F0)     
Pulse rate (per min)     
Heart rate (per min)     
Respiratory rate(per min)     
Blood pressure (mm/Hg)     
Anaemia     
Jaundice     
Cyanosis     
Lymph adenopathy     
Pedal edema     
Clubbing     
Jugular vein pulsation     
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3. CLINICAL SYMPTOMS: 
 
COMPLAINTS 1st Day 5th  Day 7th  Day 14th Day 
Sore Throat 
    
Cough 
    
Cough with 
expectoration 
   
 
Dysphagia 
    
Fever 
    
Headache 
    
Ear ache  
    
Anorexia 
    
Swollen & Erythema of 
the tonsils 
   
 
Cervical lymphadenitis 
    
Date: 
 
Station: 
 
Signature of the Guide :    Signature of the Investigator: 
 
 
Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL, 
PALAYAMKOTTAI. 
DEPARTMENT OF PG - KUZHANTHAI MARUTHUVAM 
 
PRECLINICAL AND CLINICAL STUDY ON “LASUNATHABITHAM”- A 
PEADIATRIC DISORDER AND THE DRUG OF CHOICE IS  
SUGANTHA MALLI CHOORANAM 
FORM III 
LABORATORY INVESTIGATIONS 
 
1.  Serial No: ________                                               2. Registration No: ________   
 
3. OPD No: ________                                                  4. Lab No: ________    
 
5. Name: ________________ 
 
6. Date of birth:  
             D   D     M   M        Y    Y   Y   Y 
7. Age:   _______  years  
 
8. Date of assessment: ____________________ 
 
Urine Examination: 
1. Sugar       : ______  
2. Albumin  : ______   
3. Deposits  : ______ 
 
Blood Investigations: 
 
1. TC, DC, ESR, HB,  
2. Total RBC Count  ______________ cells / cu. mm. 
 
3. Differential Count 
                    P___%     L ___%          E ___%           M ___%       B ___% 
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4. Hb _____ gms% 
 
5. ESR     at 30 minutes _______ mm    
 
 at 60 minutes _______ mm 
 
6. Blood  
  Absolute Eosinophil Count 
 
7. Special investigations : 
i. Throat swab culture  
ii. ASO TITRE (group A - β haemolytic streptococcus) 
 
 
Date: 
 
Station: 
 
Signature of the Guide :    Signature of the Investigator: 
 
 
Signature of the HOD 
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GOVT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI 
PG. DEPT. OF KUZHANTHAI MARUTHUVAM 
CONSENT FORM – IV  
 
An open clinical study to evaluate the safety and clinical efficacy of Siddha sasthric 
formulation “SUGANTHA MALLI CHOORANAM” for the management of 
“LASUNATHABITHAM” 
 
CERTIFICATE BY INVESTIGATOR 
         I certify that I have disclosed all the details about the study in the terms readily 
understood by the parent. 
Date ……………….                                  Signature………….. 
Place ……………….                                                  Name ……………… 
CONSENT OF INFORMANT 
                I have been informed to my satisfaction, by the attending physician, the 
purpose of the clinical trial, and the nature of drug treatment and followup including the 
laboratory investigations to be performed to monitor and safeguard my Son / Daughter 
body functions. 
I am aware of my right to put out of the trial at any time during the course of the trial without 
having to give the reasons for doing so. I am, exercising my free power of choice; hereby 
give my consent to be included as a subject in the clinical trial of Siddha drug “SUGANTHA 
MALLI CHOORANAM” for the treatment of “LASUNATHABITHAM”. 
Date :      Informant Signature : ..................................  
Place :     Informant Name  :....................................... 
Signature of witness   Patient Name : ........................................... 
Relationship : .......................................... 
 
! !
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GOVERNMENT SIDDHA MEDICAL COLLEGE&HOSPITAL 
PALAYAMKOTTAIPOST GRADUATE DEPARTMENT OF  
 
KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “LASUNATHABITHAM”- 
A PEDIATRIC DISORDER AND THE DRUG OF CHOICE IS  
SUGANTHA MALLI CHOORANAM 
 
S.I.No: ………….        OP/IP No: …………  Name: ……………… 
Age: …………….         Gender:  …………..   Date of Enrollment: …………. 
Date of Completion :…………. Informant: …………. Reliability :  …………… 
 
FORM IVB – WITHDRAWAL 
Date of Trial commencement  : 
Date of withdrawal from trial  : 
Reason (s) for withdrawal   : Yes /No 
Long absence at reporting   : Yes /No 
Irregular treatment    : Yes /No 
Shift of locality    : Yes /No 
Complication adverse reactions if any: Yes /No 
Exacerbation of symptoms   : Yes /No 
Pt. not willing to continue  : Yes /No 
Date : 
 
Station : 
 
 
Signature of Guide:     Signature of Investigator:  
 
 
Signature of HOD:  
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FORM IV-C – PATIENT INFORMATION SHEET 
Name of the principal investigator: ……………………………………………………. 
Name of the institution  :  GOVERNMENT SIDDHA MEDICAL  
                COLLEGE AND HOSPITAL, 
             Palayamkottai 
Information sheet for patients participating in the open clinical, trial 
 
1, _____________________________________ Studying as PG Scholar at  
GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL, 
PALAYAMKOTTAI  is doing a trail on the study “LASUNATHABITHAM”. It is a most 
common disease in children. In this regard, I am in a need to ask you few questions. I will 
maintain confidentially of your comments and data obtained. There will be no risk of 
disclosing your identity and no physical, psychological or professional risk is involved by 
taking part in this study. Taking part in this study is voluntary. No compensation will be paid 
to you for taking part in this study.  
You can choose not to take part. You can choose not to answer a specific question. 
There is no specific benefit for you if you take part in the study. However, taking part in the 
study may be of benefit to the community, as it may help us to understand the problem of 
defaulters and potential solutions.  
If you agree your child to be a participate in this study, he / she will be included in the study 
primarily by signing the concern form and then you will be given the internal medicine 
“SUGANTHA MALLI CHOORANAM” (½  gram-tds) internal for 14  days.  
 
Date : 
 
Station : 
 
 
Signature of Guide:     Signature of Investigator:  
 
 
Signature of HOD:  
!
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GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL, 
PALAYAMKOTTAI. 
DEPARTMENT OF PG KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “LASUNATHABITHAM”.  
A PEADIATRIC DISORDER AND THE DRUG OF CHOICE IS  
SUGANTHA MALLI CHOORANAM 
FORM IV D - DIETARY ADVICE FORM 
The following diet to be taken : The following food should be avoided 
 Drink adequate water 
 Drink Fruit Juice (Without Ice) 
 Take Vegetable Soup 
 Vegetable / Spinach 
 Nuts 
 Honey 
 Banana Flower 
 Sesame Seeds 
 Horse Gram 
 Chicken 
 Fish 
 Sweetened Beverages 
 Cold Water 
 Bakery Food Items 
 Oily Food 
 Excessive Salty & Spicy  
 Mangos  
 Coconut 
 Bitter Guard 
 
Date : 
 
Station : 
 
Signature of the Guide        Signature of the Investigator 
 
Signature of HOD 
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FORM – IV E ADVERSE REACTION FORM 
NATIONAL PHARMACOVIGILANCE PROGRAMME FOR 
SIDDHA DRUGS 
Reporting Form For Suspected Adverse Reactions to Siddha Drugs 
 
Please Note:  i. All Consumers/Patients and reporters information will remain  
          confidential.  
  ii. It is requested to report all suspected reactions to the concerned,  
                            even if it does not have complete data, as soon as possible.  
 
Peripheral centre code :      State : 
1. Patient /Consumer Identification (Please complete or tick boxes below as 
appropriate) 
Name  
 
 
Father Name  
 
Patient record no 
Ethnicity  
 
Occupation  
Address 
 
Village/Town 
Post/Via 
District /State 
Date of Birth/Age 
Sex:      Male /Female 
 
Weight: 
 
Degam: 
 
2. Description of the suspected adverse reactions please complete boxes below 
Date and time of initial 
observation  
 
 
 Season: 
Description of reaction  
 
 
 Geographical area: 
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3. List of all medicines/Formulations including drugs of other systems used by the 
patient during the reporting period:  
Medicine 
Daily 
dose 
Route of 
administration  
Vehicle – 
Adjuvant 
Date 
Diagnosis for which 
medicine taken Starting Stopped 
Siddha  
 
 
 
 
 
 
     
Any other 
system of 
medicines  
 
 
 
     
  
 
4. Brief details of the Siddha Medicine which seems to be toxic : 
 
Details Drug – 1 
a) Name of the Medicine   
b) Manufacturing unit and batch no. and date  
c) Expiry date  
d) Purchased and obtained from  
e) Composition of the formulation / part of the 
drug used 
 
  
 
 Dietary restrictions if any 
 Whether the drug is consumed under institutionally qualified medical supervision or 
used as self medication  
 Any other relevant information  
 
  
xlviii 
 
5. Treatment provided for adverse reaction: 
 
 
6. The result of the adverse reaction /side effect / untoward effects ( Please complete the 
boxes below )  
Recovered Not 
recovered: 
 
Unknown Fatal If fatal 
Date of death: 
Severe Yes /No Reaction abated after drug stopped or dose reduced 
  
Reaction reappeared after re introduction : 
 
 
 
Was the patient admitted to hospital? If yes, 
give name and address of hospital  
 
 
7. Any laboratory investigation done to evaluate other possibilities? If yes specify: 
 
 
8. Whether the patient is suffering with any chronic disorders? 
 
Hepatic    Rental  Cardiac Diabetes Malnutrition  
 
 
Any Others  
 
9. H/O previous allergies /Drug reactions: 
 
10. Other illness (please describe): 
 
 
 
 
Type (please tick):Nurse/Doctor/Pharmacist/Health 
worker/Patient/Attendant/Manufacturer/ Distribution /Supplier /Any other    (please 
Specify) 
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Name : 
 
 
Address: 
 
 
 
Telephone /E-mail if any: 
 
 
 
 
 
 
 
 
Signature of the reporter       Date : 
 
Please send the completed from to  
 
 
From 
Government Siddha Medical College 
& Hospital, Palayamkottai, Post 
Graduate Department of Kuzhanthai 
Maruthuvam 
 
 
 
 
 
 
  
To 
The co- ordinator,  
Pharmacovigilence, 
Government Siddha Medical 
College and Hospital, 
Palayamkottai. 
  
l 
 
 
This Filled- in ADR report may be send within one month of observation / occurrence of 
ADR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date : 
 
Station: 
 
 
Signature of Guide:   Signature of the Investigator 
 
 
Signature of HOD  
 
 
 
  
 
 
 
 
 
 
 
Who can report?  
 Any health care professionals like Siddha Doctors 
/Nurses /Siddha Pharmacists / Patients Etc.,   
What to report? 
 All reactions, Drug interactions 
Confidentiality  
 The patient’s identify will be held in strict confidence 
and protected to the fullest extent 
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GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI 
BRANCH-IV KUZHANDHAI MARUTHUVAM 
Form IV F 
Admission – Discharge Proforma 
Name of the Medical Unit: 
Name of the Medical Unit: 
I.P. NO : Occupation : 
Bed no : Income : 
Ward  : Nationality : 
Name :  Religion : 
Age : Date of  Admission : 
Sex : Date of discharge : 
Permanent address: : Diagnosis : 
Temporary address: :      Results : 
Informant : Medical officer : 
 
S.NO CLINICAL    FEATURES 
(Signs and symptoms) 
During 
Admission 
During Discharge 
1 Sore throat   
2 Cough   
3 Cough with expectoration   
4 Dysphagia   
5 Fever   
6 Headcahe   
7 Earache   
8 Anorexia   
9 Swollen and Erythema of the 
tonsils 
  
10 Cervical lymphadenitis   
 
Date :                                                      
 
Place: 
                                         Signature of the Medical officer  
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
 
PRECLINICAL AND CLINICAL STUDY ON “LASUNATHABITHAM”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS 
SUGANTHA MALLI CHOORANAM 
 
FORM V-DRUG COMPLIANCE  
 
S.I.No: ………….        OP/IP No: …………  Name: ……………… 
Age: …………….         Gender:  …………..   Date of Enrollment: …………. 
Date of Completion :…………. Informant: …………. Reliability :  …………… 
 
NAME OF THE DRUG     : SUGANTHA MALLI CHOORANAM 
FORM OF THE DRUG      : CHOORANAM 
ADMINISTRATION & ADJUVANT : PER ORAL (Internal ) & milk 
DOSE & DURATION      : ½ gram tds for 14 days 
NO OF DRUG PACKS GIVEN     : ________________ 
NO OF DRUG PACKS  RETURNED : ________________ 
DAY 
DATE OF 
DRUG 
INTAKE 
MORNING AFTERNOON EVENING 
DAY 1     
DAY 2     
DAY 3     
DAY 4     
DAY 5     
DAY 6     
  
liii 
 
DAY 7     
DAY 8     
DAY 9     
DAY 10     
DAY 11     
DAY 12     
DAY 13     
DAY 14     
 
 
 
Date :                                                      
 
Station 
 
 
Signature of the Guide      Signature of Investigator:  
 
 
Signature of the HOD 
 
  
